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RIASSUNTO 
INTRODUZIONE. L'uso di modelli murini transgenici ha permesso la recente 
identificazione di una regolazione reciproca tra osso, metabolismo energetico e 
ormoni sessuali. L’osteocalcina, una proteina della matrice ossea che subisce delle 
modifiche post-traduzionali vitamina-K dipendenti ed è classicamente implicata nella 
regolazione delle dimensioni e la forma dei cristalli di idrossiapatite, sembra essere 
nella sua forma circolante un ormone e non un semplice marcatore di 
rimaneggiamento osseo. La somministrazione di osteocalcina nella sua forma 
sottocarbossilata regola l’espressione genica e proteica negli adipociti, nelle cellule β 
pancreatiche e del Leydig attraverso un recettore associato a una proteina G, il 
recettore GPRC6A, con una selettività genere-specifica. Sono stati condotti numerosi 
studi che hanno associato i livelli di osteocalcina circolante sia con parametri di 
controllo gluco-metabolico che con fattori di rischio cardiovascolare. La gran parte 
degli studi clinici, tuttavia, non ha considerato né l'influenza dei livelli di vitamina K 
né ha rilevato l’osteocalcina nelle varie forme di differente carbossilazione. È 
interessante sottolineare, infine, come il recettore GPRC6A sia responsabile della 
mediazione degli effetti non-genomici degli androgeni e, analogamente, il recettore 
putativo dell’SHBG sembra essere un recettore associato a  una proteina G. 
OBIETTIVO dello STUDIO. Obiettivo dello studio è stato studiare in un approccio in 
due fasi, supportati dalle osservazioni cliniche, le possibili interazioni tra 
l’osteocalcina, SHBG e il recettore GPRC6A a livello computazionale e, 
successivamente, verificarle in un modello sperimentale cellulare in vitro.  
MATERIALI e METODI. I parametri clinici e di laboratorio sono stati studiati in una 
coorte di 91 pazienti, che includevano pazienti obesi e soggetti sani di controllo con 
un disegno trasversale. Un’analisi della struttura proteica tridimensionale e una di 
docking sono state elaborate con rispettivamente quattro (i.e. TM-align, FATCAT, 
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TriangleMatch, TopMatch) e tre (i.e. GRAMM-X, ZDOCK, PatchDock) algoritmi 
bioinformatici. La piattaforma iClickMD-min script é stata utilizzata per l’analisi 
computazionale della struttura conformazionale dell’osteocalcina, ottenuta tramite 
il software MOE, in diverse forme di carbossilazione e in presenza o assenza di ioni 
calcio. Tali analisi sono state integrate con simulazioni di dinamica molecolare, i cui 
risultati sono stati successivamente confrontati con quelli ottenuti dalle analisi 
spettroscopiche. I risultati sono stati validati con studi di espressione genica e 
proteica e saggi di spiazzamento con tecniche di immunofluorescenza e 
citofluorimetria su colture di cellule HEK-293T.   
RISULTATI. Il nostro studio dimostra per la prima volta l'esistenza di una 
competizione per un sito di legame specifico tra l’osteocalcina e SHBG su cellule 
umane che esprimono il recettore GPRC6A. Un’analisi predittiva computazionale 
supporta i risultati, identificando nella sequenza amminoacidica compresa tra i 
residui residui Gly145 e Leu161 di SHBG l’interfaccia più probabile. I nostri 
esperimenti descrivono, inoltre, per la prima volta la struttura dell’osteocalcina 
umana nelle sue varie forme di carbossilazione. L'influenza del legame degli ioni 
calcio sulla struttura dell’osteocalcina sembra, tuttavia, essere più forte della 
presenza di un differente stato di carbossilazione. I nostri dati clinici mostrano, 
infine, uno squilibrio tra le differenti forme di osteocalcina nella coorte di soggetti 
obesi affetti da ipogonadismo. 
CONCLUSIONI. L’approccio utilizzato nel presente studio offre un modello di 
indagine mirata sull’uomo con il potenziale di poter identificare nuove vie di 
regolazione e svelare prospettive terapeutiche. Il supporto bioinformatico 
all’interpretazione degli esperimenti in vitro offre i fondamenti per la sintesi del 
peptide precedentemente descritto, le cui implicazioni biologiche potranno essere 
preliminarmente validate sullo stesso modello, al fine di indagare le basi della 
regolazione integrata tra tessuto osseo, metabolismo energetico e ormoni sessuali.  
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ABSTRACT 
INTRODUCTION. The use of mouse genetics recently highlighted coordination by 
endocrine regulation between bone, energy metabolism, and endogenous sex 
hormones. Osteocalcin, a bone matrix protein that regulates hydroxyapatite size and 
shape through its vitamin‑K-dependent γ‑carboxylated form, unraveled 
endocrinological functions in its circulating forms, that are not only simple markers 
of bone formation. Undercarboxylated osteocalcin administration regulates gene 
and protein expression in adipocytes, in pancreatic β cells, and in Leydig cells by a G 
protein-coupled receptor, GPRC6A receptor, with a potential gender selectivity. 
Total serum osteocalcin concentrations in humans are inversely associated with 
measures of glucose metabolism and cardiovascular risk factors; however, human 
data are inconclusive with regard to the role of uncarboxylated osteocalcin because 
most studies do not account for the influence of vitamin K or differentiate between 
the different γ‑carboxylated forms of osteocalcin. Intriguingly GPRC6A receptor 
mediates also the non-genomic effects of androgens and, although the information 
about SHBG-receptor structure is not conclusive, evidence seems to suggest that a G 
protein-coupled receptor is involved. 
AIM of the STUDY. Starting from clinical observations, we investigated the protein-
protein interaction computational predictors of osteocalcin and SHBG with GPRC6A 
receptor, and we validated experimentally in vitro in  a two-step approach. 
MATHERIAL and METHODS. Clinical and biochemical characteristics were studied in 
a cohort of 91 obese patients and healthy controls in a cross-sectional study. 3-D 
protein structure alignment analysis and protein docking analysis were resolved with 
a four (i.e. TM-align, FATCAT, TriangleMatch, TopMatch) and three (i.e. GRAMM-X, 
ZDOCK, PatchDock) different algorithms approach, respectively. ClickMD-min script 
was used as a molecular dynamic platform for computational analysis of the 
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conformational structure of osteocalcin in presence or absence of Ca2+, developed 
with MOE software. Steered molecular dynamics simulations related to the 
carboxylation state were performed, and the data compared with the spectroscopic 
techniques results.  Gene and protein expression analysis and cell-surface receptor 
binding assays (i.e. immunofluorescence and flow cytometry analysis) on HEK-293T 
cells experimentally validated  the former results in vitro.   
RESULTS. Our study shows for the first time the existence of the competition for a 
specific binding site between osteocalcin and SHBG on human cells expressing 
GPRC6A receptor. The results are supported by a computational prediction analysis, 
describing amino acid residues of SHBG from Gly145 to Leu161 as a highly predicted 
interface. Our experiments describe the structure of human osteocalcin in its 
carboxylated and undercarboxylated forms for the first time. The influence of the 
binding of Ca2+ on osteocalcin structure seems to be stronger than the presence of 
γ-carboxylated glutamic acid residues. Our clinical data show an imbalance between 
the γ‑carboxylated forms of osteocalcin in a cohort of hypogonadic obese an 
overweight patients, with decreased levels of SHBG and altered levels of the other 
sex hormones. 
CONCLUSIONS. The current two-step approach offers a target approach of 
investigation directly in humans, that has the potential to identify novel 
pathophysiological pathways as well as novel therapeutic possibilities. The 
computational basis of the possible binding of SHBG and osteocalcin has been 
experimentally validated and can directly lead to the synthesis of a peptide, whose 
physiological and therapeutic implications represent a feasible perspective for 
future research in an area of paramount importance, such as the cross-talk between 
bone, energy metabolism, and endogenous sex hormones. 
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INTRODUCTION 
Osteocalcin synthesis and catabolism 
Osteocalcin, also called bone Gla protein or BGP, was the first member of the 
calcium binding and vitamin K-dependent protein family not associated with blood 
coagulation to be described, sequenced, and characterized (Price et al., 1976a; Price 
et al., 1976b). Osteocalcin (OC) is secreted mainly by osteoblasts, only in the late 
stage of their differentiation, after the arrest of proliferation and under the control 
of the Runx2/Cbfa1 transcription factor (Carvallo et al., 2008). Lower levels of 
osteocalcin has been reported in endothelial progenitor cells (Gössl et al., 2008), 
myeloid calcifying cells (Fadini et al., 2011), in vascular smooth muscle cells (VSMCs) 
(Spronk et al., 2001), and in the brain, intestine and kidney (Fleet et Hock, 1994). 
Moreover, our group reported evidence for osteocalcin production, storage, and 
secretion, upon activation with an endogenous mechanism, in peripheral blood 
platelets and in bone marrow megakaryocytes (Thiede et al., 1994; Foresta et al., 
2012), and in adipose tissue and during all stages of adipogenesis (Foresta et al., 
2010). Osteocalcin mRNA has also been detected in several non-osseous tissues, but 
the RNA splicing was found to be incomplete (Jung et al., 2001). 
Osteocalcin is encoded in human by the Bone γ-Carbossiglutamate gene, a single-
copy gene located on chromosome gene 1q25.31 (Puchacz et al., 1989; Raymond et 
al., 1999). The transcription of this gene requires modifications in the chromatin 
structure and nucleosome organization, that render the regulatory sequences at 
promoter level accessible to the cognate transcription factors (Shen et al., 2003). 
The key regulators of Osteocalcin transcription have been recognized by Runx2, the 
essential regulator of basal bone-specific transcription, and vitamin D3, the principle 
enhancer of Osteocalcin expression (by 3 to 5-fold times) (Price et Baukol, 1981; 
McDonnell et al., 1989; Ozono et al., 1990), after the initiation of basal transcription. 
The transcription starts at the proximal region of the promoter, which contains 
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Runx2 and TCF/LEF sites, and continues at the distal regions which contains Runx2 
and AP-1 binding sites and regulatory sequences responsive to vitamin D3. Other 
regulatory factors include parathyroid hormone (PTH) (Yu et Chandrasekhar, 1997), 
estrogens (E) (Qu et al., 1998), glucocorticoids, (Shalhoub et al., 1998), growth 
factors (Hughes-Fulford et Li, 2011) and cyclic adenosine monophosphate (cAMP) 
(Boudreaux et Towler, 1996). Besides its role in the regulation of the transcription 
gene, vitamin D3 regulates Osteocalcin gene expression at post-translational level, 
by stabilizing the Osteocalcin mRNA, as demonstrated in osteoblast-like cells 
(Mosavin et Mellon, 1996).  
After the synthesis of pre-promolecule with 98 amino acids and 11 KDa molecular 
weight, several post-translational modifications are required to obtain the active 
form of 49 residues and around 5.8 KDa molecular weight. A 23-signal peptide is 
cleaved and three carboxyl groups in propeptide are added to three glutamic acid 
residues (Glu) in the presence of vitamin K, the cofactor of carboxylase. (Lian et 
Friedman, 1978; Price et al., 1983) The vitamin K group consists of structurally 
similar, fat-soluble, 2-methyl-1,4-naphtoquinones, which transform Glu residues 
into γ-carboxyglutamic acid residues (Gla), through carboxylation process (Figure 1).  
 
Figure 1. Vitamin K is required for the formation of γ‑carboxyglutamic acid residues (Gla). γ‑
carboxyglutamic acid residue is a unique amino acid that is created by vitamin-K-dependent post-
translational modification of specific glutamic acid residues in all Gla-containing proteins, including 
osteocalcin. This process is inhibited by warfarin. (modified from Booth et al., 2012) 
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The vitamin K dependent carboxylation of osteocalcin has been shown to occur in 
bone tissue in organ culture (Lian et Friedman, 1978) and in isolated bone cells in 
tissue culture (Nishimoto and Price, 1980). The carboxylase has a high affinity 
binding site for the sequence contained in the mature form (Stanley et al., 1999; 
Frazao et al., 2005). Moreover, the carboxylase enzyme has high affinity for the 
domain formed by Gla residues (Benton et al., 1995). In most species, all three Glu 
residues are fully carboxylated. However, in humans, osteocalcin in bone is 
incompletely carboxylated. 
At the end of post-translational modifications, the mature form is released in bone 
matrix, where the major part binds calcium ions (Ca2+) (Hoang et al., 2003). The 
unbound fraction is released into the bloodstream (Price et Nishimoto, 1980); 
circulating osteocalcin consists of intact osteocalcin (one-third), N-terminal 
osteocalcin fragments 1-43 (one-third) and unidentified fragments (one-third), due 
to the action of proteolytic enzymes. Recently, Ferron et al. demonstrated a pH-
dependent mechanism of activation for osteocalcin in mouse and human 
osteoblasts (Ferron et al., 2010). Since an acid pH is the only known chemical 
condition allowing protein decarboxylation (Poser and Price, 1979; Engelke et al., 
1991), bone resorption, which occurs at pH 4.5, provides an ideal setting to 
decarboxylate and activate osteocalcin, using the huge amount of osteocalcin stored 
in the bone extracellular matrix (ECM). The levels of carboxylated osteocalcin and 
undercarboxylated osteocalcin in cultured differentiated osteoclasts on bovine 
cortical bone slides devitalized (to exclude any endogenous osteoblastic) resulted in 
a 2-fold increase in the undercarboxylated/carboxylated osteocalcin ratio (Ferron et 
al., 2010). However, this mechanism account only for a part of the 
undercarboxylated osteocalcin, another in vitro study, in fact, showed that warfarin 
increases undercarboxylated osteocalcin from 29% to 54% (Henneicke et al., 2009). 
Human osteocalcin concentrations in bone and in the circulation are only 20% of 
those found in other species. 
4 
 
Osteocalcin structure 
Osteocalcin proteins have of 46-50 amino acid residues depending on the species 
(Frazao et al., 2005). Compared with the human sequence, the overall protein 
sequence is highly conserved in most species (80-95%), but to a lesser extent in the 
frog and chicken (70%), mouse (60%) and bony fish (40%) (Hoang et al., 2003). 
However, considerable sequence variation exists at other regions (Figure 2).  
 
Figure 2. Sequence alignment of osteocalcin. Protein sequence with the secondary structure 
elements are indicated and the conserved residues highlighted (green, red, blue, yellow, orange and 
grey indicate conserved, acidic, basic, cysteine, asparagine and glycine residues, respectively). 
Positions are identified as conserved if more than 85% of the residues are identical, or similar if 
hydrophobic in nature. γ indicates a Gla residue, open triangles and circles indicate hydrophobic core 
and Ca2+-coordinating surface, respectively. (modified from Hoang et al., 2003) 
Conserved elements in all osteocalcin sequences examined include a single disulfide-
bonded loop (i.e. Cys23-Cys29), and the homology of the EXXXEXCEXXXXC motif (i.e. 
GluXXXGluXCysGluXXXXCys). EXXXEXCEXXXXC motif, in particular, including the 
three Glu residues located at positions 17, 21, and 24 (according the numbering of in 
human and porcine osteocalcin) undergoing to the γ- carboxylation process, is highly 
conserved (Hoang et al., 2003; Frazao et al., 2005), arguing for its functional 
importance. Carboxylation is an ordered process with Glu21 and Glu24 residues 
being carboxylated first, followed by Glu17 in humans (Benton et al., 1995). 
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However, Glu17 is γ-carboxylated only in about 9% of human osteocalcin (Poser et 
al., 1980). The partial carboxylation of human osteocalcin was proposed to be due, 
at least in part, to defective post-translational carboxylation prior to secretion, not 
to decarboxylation of the mature protein after secretion (Frazao et al., 2005). γ-
carboxylation of Glu residues is thought to increase affinity of osteocalcin for Ca2+ 
and is essential for the interaction of osteocalcin with bone in vivo and for the 
specific interaction with bone hydroxyapatite (HA) in vitro, thus contributing to bone 
formation (Poser and Price, 1979; Pastoureau et al., 1993). Circular dichroism (CD) 
(Hauschka and Carr, 1982; Atkinson et al., 1995 ) and nuclear magnetic resonance 
(NMR) (Atkinson et al., 1995; Dowd et al., 2001; Dowd et al., 2003) analysis indicate 
that fully γ-carboxylated chicken and bovine osteocalcin in solution are largely 
unstructured in the absence of calcium and that only after addition of physiological 
Ca2+ concentrations (1-2 mM), they undergo a transition to a folded state  displaying 
highly flexible N- and C-terminal regions and characterized by a protein core formed 
by three α-helices stabilized by the previously described single disulfide bridge and 
orienting the Gla residues on the same face of osteocalcin molecule. Similar 
conclusions were also drawn from the crystallographic structures of porcine (Hoang 
et al., 2003) and fish (Frazao et al., 2005) osteocalcin. Specifically, porcine osteoalcin 
(i.e. from residues Pro13 to Ala49) formed a tight globular structure comprising a 
previously unknown fold (no matches in the DALI database, Hohm  and Sander, 
1993) with a topology consisting, from its N-terminal, of three α-helices and a short 
extended strand. α-helices H1 and H2 are connected by a type III turn structure from 
Asn26 to Cys29 and formed a V-shaped arrangement that was stabilized by an 
interhelix disulphide bridge involving Cys23 and Cys29 (Figure 3) (Hoang et al., 
2003). α-helix H3 was connected to α-helix H2 by a short turn and was aligned to 
bisect the V-shape arrangement of α-helices H1 and H2. The three α-helices 
together composed a tightly packed core involving conserved hydrophobic residues 
Leu16, Leu32, Phe38, Ala41, Tyr42, Phe45 and Tyr46. The overall tertiary structure 
6 
 
was further stabilized by a hydrogen bond (HB) interaction between two invariant 
residues, Asn26 in the α-helices H1 and H2 linker and Tyr 46 in α-helices H3 (Hoang 
et al., 2003). 
Projection of conserved residues onto the molecular surface of the porcine 
osteocalcin structure showed an extensive negatively charged surface centering on 
α-helices H1 (solvent-exposed surface area 586 Ȧ2). Notably, all three Gla residues 
implicated in HA binding were located on the same surface of α-helices H1 and, 
together with the conserved residue Asp30 from α-helices H2, coordinated five Ca2+ 
in an elaborate network of ionic bonds (Figure 3) (Hoang et al., 2003).  
 
Figure 3. Direct structural analysis of osteocalcin by NMR imaging and X‑ray crystallography 
predicted a tight globular structure comprised of three α‑helices, a C‑terminal hydrophobic core and 
an unstructured N‑terminus. All three Gla residues were found in the first helical region (α‑helix H1). 
The γ‑carboxyglutamic acid residues are complementary to the calcium ions on the c‑axis of the 
hydroxyapatite crystal lattice, and are positioned to control crystal size and shape within the 
constraints of the collagen fibril. (modified from Hoang et al., 2003) 
The N-terminal part of OC exhibits a considerable sequence variation (Hauschka et 
al, 1989; Viegas et al., 2002), but unfortunately was not considered in the Hoang 
model (Hoang et al., 2003). The C-terminal part of osteocalcin seems to possess 
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chemotactic activity (Mundy and Poser, 1983). However, Frazao states that the 
residues at N- and C-terminal regions, out of the tight globular arrangement of the 
three α-helices, have essentially no secondary structure characteristics in the 
porcine and fish models (Frazao et al., 2005). Finally, sedimentation equilibrium data 
suggested that osteocalcin exists as a monomer in vivo (Hoang et al., 2003). 
Osteocalcin function 
The several interesting properties of osteocalcin were highlighted since long ago: (i) 
extremely abundance in the bone ECM (Hauschka et al., 1989); (ii) low-level of 
circulating osteocalcin in blood plasma (Price and Nishimoto, 1980); (iii) derivation 
from higher molecular weight precursor proteins (Hauschka, 1979; Nishimoto and 
Price, 1980) (iv) specific Gla-dependent binding of Ca2+ ions (Hauschka et Gallop, 
1977; Poser and Price, 1979; Gallop et al., 1980); and (v) Ca2+-induced transition to 
the α-helical conformation (Hauschkan et  Carr, 1982). 
The first piece of evidence that osteocalcin is a determinant of bone formation was 
obtained in mice lacking of Osteocalcin (Osteocalcin-/- mice), that developed a late-
onset phenotype marked by modestly increased bone mass and bones of improved 
functional quality (Ducy et al., 1996), suggesting that osteocalcin directly inhibits 
osteoblastic bone formation without impairing bone resorption or mineralization. 
Bone mineral content was unaffected, but subsequent analysis of the crystal 
properties of hydroxyapatite showed altered mineral composition in the cortical 
bone of Osteocalcin-/- mice (Boskey et al., 1998), being immature at small-angle X‑
ray scattering. Conversely, subsequent studies suggested that osteocalcin improved 
both the initial adherence of osteoblast-like cells to biocement, without affecting 
the proliferation of cells (Knepper-Nicolai et al., 2002), and to  
hydroxyapatite/collagen composites (Rammelt et al., 2005). Further studies showed 
that osteocalcin was implicated in bone resorption, promoting differentiation of 
osteoclast progenitors and enhancing chemotaxis and activity in studies in vivo (Lian 
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et al., 1984; Chenu et al., 1994, Ingram et al., 1994) and in vitro (Malone et al., 1982; 
Liggett et al., 1994; Mundy et Poser, 1983). Finally, despite osteocalcin abundance in 
a mineralized bone ECM and protein’s high affinity for mineral ions due to Gla 
residues suggested that this protein was involved in bone ECM, loss- and gain-of-
function mutations in Osteocalcin have unambiguously established, that this was not 
the only action (Figure 4) (Ducy et al., 1996; Murshed et al., 2004). Osteocalcin-/- 
mice, given the abundance of osteocalcin and its restriction to bone and specificity 
to hydroxyapatite, had no overt phenotypic abnormalities (Ducy et al., 1996), 
despite that changes in optimal crystal size and orientation of HA, affecting both 
bone quantity and quality, were revealed at small-angle X‑ray scattering (Boskey et 
al., 1998; Poundarik et al., 2011) 
All three Glu residues in the osteocalcin molecule are fully carboxylated in most 
species. However, osteocalcin in bone and serum is incompletely carboxylated and 
Ca2+-free osteocalcin can be detected in circulating plasma in humans, as previously 
specified, and its levels are generally associated both with higher osteoblast activity 
(Garnero et al., 1994) and with bone turnover (Ivaska et al., 2004). Moreover, since 
Ducy`s  Osteocalcin-/- mice model, circulating osteocalcin showed important 
endocrine functions. The first hypothesis that skeleton may act as an endocrine 
organ regulating energy metabolism, arose observing the abnormal amount of 
visceral fat in Osteocalcin-/- mice. This hypothesis was verified by showing that, 
unlike wild-type osteoblasts,  Osteocalcin-/- osteoblasts cannot induce insulin 
secretion by pancreatic β cells (Lee et al., 2007). Accordingly, Osteocalcin-/- mice 
were hyperglycemic, hypoinsulinemic, and insulin resistant in liver, muscle, and 
white adipose tissue. Islets’ size and number, β-cell mass, pancreas insulin content, 
and insulin immunoreactivity were all markedly decreased in Osteocalcin-/- mice. Fat 
mass was increased and associated with a higher adipocytes number and serum 
triglyceride levels in Osteocalcin-/- mice (Lee et al., 2007). These features were 
associated with decreased levels of serum adiponectin, an adipokine known to 
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enhance insulin sensitivity. In particular, the decrease in osteocalcin-induced insulin 
sensitivity occurs, at least in part, through adiponectin, though the decrease in 
insulin secretion is a direct consequence of osteocalcin deficiency (Lee et al., 2007). 
Surprisingly, the metabolic phenotype of Osteocalcin-/- mice were the mirror image 
of the one observed in mice lacking of  Embrionic stem cell phosphatase (Esp-/- mice), 
suggesting that in the latter there is a gain of osteocalcin activity (Figure 4). Esp (also 
known as the protein tyrosine phosphatase receptor type Ptprv gene) is expressed in 
the mouse osteoblast and the mouse Sertoli cells and the embryonic stem cell and 
encodes the protein tyrosine phosphatase termed OST-PTP (Mauro et al., 1994).  
Esp-/- mice were hypoglycemic and hyperinsulinemic (Lee et al., 2007; Ferron et al., 
2008). Insulin secretion and sensitivity were increased in Esp-/- mice, whereas mice 
overexpressing Esp in osteoblasts were glucose intolerant because of a decrease in 
insulin secretion and sensitivity, in pancreatic β cells and in liver, muscle, and white 
adipose tissue, respectively (Lee et al., 2007). In a co-culture assay, in which wild 
type (WT) cells were separated by a filter, osteoblasts enhanced Insulin expression 
of 40%, next to insulin secretion by islets or β cells, and Adiponectin expression, and 
subsequently adiponectin secretion, by adipocytes. The enhancement of the 
expression was to a higher extent with Esp-/- osteoblasts than wild-type osteoblast 
(Lee et al., 2007). Moreover, the glucose intolerance phenotype of Osteocalcin-/-  
mice was corrected by removing one allele of Esp from these mice (Lee et al., 2007). 
Overall the previous data indicate that Esp-/- mice are a gain-of-function model for 
osteocalcin the newly discover actions of osteocalcin on metabolism.  
Lee et al. showed that the level of γ-carboxylation, the main post-translational 
modification of osteocalcin, was different in wild-type and Esp-/- mice (Lee et al. 
2007). Following a 15 min incubation period, 90% of osteocalcin present in the 
serum of wild-type mice was bound to HA, whereas only 74% was present using 
serum from Esp-/- mice. Moreover, wild-type osteoblasts treated with warfarin, an 
inhibitor of γ-carboxylation (Berkner, 2005), resulted in a marked decrease in the 
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percentage of osteocalcin bound to HA, and warfarin-treated osteoblasts induced 
Adiponectin expression to a significantly higher extent than vehicle-treated 
osteoblasts. Only undercarboxylated osteocalcin in cell-based in vitro assays showed 
that could induce expression of Adiponectin in adipocytes, and of Insulin and 
CyclinD1, a molecular marker of cell proliferation, in islets (Lee et al., 2007). No 
effects were demonstrated in the former model by co-incubation with osteocalcin 
with fully carboxylated Gla residues. Ferron et al. data confirmed the previously, in 
fact when rat insulinoma INS-1 cells treated with carboxylated osteocalcin (i.e. at pH 
7.5) or undercarboxylated osteocalcin (i.e. at pH 4.5), only the latter form could 
increase insulin secretion to the same extent of recombinant undercarboxylated 
osteocalcin (i.e. bacterially produced),  used as a positive control  (Figure 4) (Ferron 
et al., 2008). 
Esp-/- mice fed with a high fat diet gained significantly less weight than wild-type 
mice and did not develop glucose intolerance or insulin resistance as wild-type mice 
did (Lee et al., 2007), showing in vivo that Esp-/- mice are intrinsically protected.  The 
protein encoded by Esp, in fact, is not secreted and therefore cannot be a hormone. 
On the other side, Osteocalcin-/- mice receiving exogenous osteocalcin had a 
decreased blood glucose levels at the 30, 60, and 120 min time points of this glucose 
tolerance test  assay and an increased insulin secretion compared to those not 
receiving recombinant undercarboxylated osteocalcin (Lee et al., 2007). Moreover, 
wild-type mice receiving exogenous osteocalcin (3 ng/h) did not develop an obesity 
phenotype or a glucose intolerance phenotype when fed a high-fat diet (Ferron et al, 
2008). Pico to nanomolar amounts of exclusively recombinant undercarboxylated 
osteocalcin were able to regulate glucose metabolism, to affect insulin sensitivity, 
and to regulate fat mass in wild-type mice (Ferron et al, 2008). In wild-type mice fed 
a high-fat diet, daily injections of osteocalcin partially restored insulin sensitivity and 
glucose tolerance, displaying additional mitochondria in their skeletal muscle, having 
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increased energy expenditure, being protected from diet-induced obesity and 
hepatic steatosis (Ferron et al., 2012).  
 
Figure 4. Model of the role of osteocalcin in glucose metabolism in mice. The presence of 
undercarboxylated osteocalcin in human circulation could be the consequence of two separate 
processes: incomplete carboxylation of osteocalcin, linked or not to suboptimal vitamin K intake, or 
decarboxylation during osteoclast resorption. Insulin signaling in osteoblasts limits the production of 
osteoprotegerin, an inhibitor of osteoclast maturation. This mechanism facilitates osteoclast bone 
resorption, producing an acid environment that decarboxylates (and hence activates) intact 
osteocalcin. OST-PTP/PTN 1+2 dephosphorylates the insulin receptor in osteoblasts leading to 
inhibition of insulin signaling. abbreviations: cOC, carboxylated osteocalcin; OPG, osteoprotegerin; 
ucOC, undercarboxylated osteocalcin. (modified from Booth et al., 2012) 
These experiments are consistent with the notion that osteocalcin is a molecule 
secreted and represent a hormone, whose action and regulation seems to be linked 
to osteocalcin secretion in mice. 
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Osteocalcin G protein-coupled receptor 
The final element necessary to complete a putative endocrine loop mediated by 
osteocalcin was the identification of a tissue-specific receptor. G protein-coupled 
receptors make up one of the largest protein families in humans and are cell-surface 
receptors that can be activated by a broad range of ligands (Bockaert et Pin, 1999). A 
large proportion of physiological stimuli and of current drugs (27%–45%) exerts their 
effect via G protein-coupled receptors, but the majority of the receptors in this 
protein superfamily are as yet untapped for potential therapies (Overington et al., 
2006).  
The first evidence that the signaling pathway of osteocalcin could be mediated by a 
protein-coupled receptor, was the discovery that an orphan G protein-coupled Ca2+ 
receptor, widely expressed in bone and osteoblasts, was responsive to osteocalcin 
(Pi et al., 2005). Osteocalcin in the presence of extracellular Ca2+ significantly 
enhanced serum response element (SRE)-luciferase activity in a cell line stably 
expressing GPRC6A receptor, depending on the prevailing level of extracellular Ca2+ 
(Pi et al., 2000; Pi et al., 2005). Oury et al. achieved the same goal with an interesting 
indirect approach (Oury et al. 2011). After characterization of the signaling pathway 
used by osteocalcin  (i.e. induction of cAMP production, but not tyrosine 
phosphorylation, ERK activation, or intracellular calcium accumulation in Leydig 
cells),  a G protein-coupled receptor emerged to be the most appropriate candidate. 
Moreover, taking the advantage of the dichotomy of fertility regulation of 
osteocalcin between male and female mice, only 22 out of 103 orphan GPCRs tested 
were predominantly expressed in testes compared to ovary. 4 out of these 22 were 
enriched in Leydig cells, including Gprc6a-/-, whose deletion resulted in a metabolic 
and fertility phenotype similar to that of Osteocalcin-/- mice, characterized by 
glucose intolerance, impaired insulin secretion, and under-masculinization in vivo (Pi 
et al., 2008). Moreover, osteocalcin directly bound to wild-type cells expressing 
Gprc6a but not to Gprc6a-/- cells (Oury et al., 2011). Interestingly, GPRC6A receptor 
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is highly expressed in mouse pancreatic tissue and in the mouse TC-6 pancreatic β-
cell line, and recombinant osteocalcin stimulates insulin secretion in the pancreas (Pi 
et al., 2011) 
GPRC6A receptor belongs to a small family of dimeric G protein-coupled receptor, 
Family C/Glutamate family, which includes eight metabotropic glutamate receptors 
(mGluR1-8), one calcium sensing receptor (CaR), two γ-aminobutyric acid receptor 
(GABABR1-2) as well as several taste (e.g. T1R1, T1R2, and T1R3) and orphan 
receptors (RAIG1, GPRC5B-5D, and GABABL) (Wellendorph et Braüner-Osborne, 
2004; Braüner-Osborne et al., 2007). GPRC6A receptor was conserved through 
evolution. 
Gprc6A gene is located on chromosome band 6q22.31. The longest and most 
abundant variant was named isoform 1 and displayed an open-reading frame of 
2778 nt (926 aa). The existence of two additional Gprc6a isoforms (2 and 3); the two 
isoforms carry in-frame deletions in the ATD (Wellendorph et al., 2004). Gprc6a has 
a broad expression profile in humans, mice, and rats (Kuang et al., 2005; Pi et al., 
2005; Wellendorph and Braüner-Osborne, 2004; Wellendorph et al., 2007). Gprc6a 
is expressed nearly all tissues tested (except the small and large intestines and 
parathyroid gland), with highest levels in kidney, skeletal muscle, testis, brain, and 
leucocytes (Wellendorph et al., 2004; Kuang et al., 2005; Pi et al., 2005). All three 
isoforms are expressed in mammalian cells, but are poorly expressed on the cell 
surface. Except for the kidney, where isoforms 1 and 2 appear equally expressed, 
isoforms 2 and 3 are generally less abundant than isoform 1.  
The Family C receptors have a characteristic large, extracellular, ligand-binding 
venus fly trap domain (VFTM), a Cys-rich region, a seven-transmembrane (7-TM) 
bundle and an intracellular C-terminal (Braüner- Osborne et al., 2007). The calcium-
sensing receptor is its closest homologue with a 34%  amino acid residues sequence 
identity, despite the bears the highest resemblance is with an odorant goldfish 5.24 
receptor (Wellendorph et al., 2004) (Figure 5).  
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Figure 5. Hypothetical model of ligand activation and allosteric modulation of GPRC6A. GPRC6A 
consists of a VFTM for sensing nutrients and the 7-TM domain and like other members of this family 
may function as a dimer. The orthotopic agonists, such as L-Arg and Ca2+, which are likely to be the 
natural ligands, binding sites are located adjacent to each other in the VFTM, whereas binding sites 
for allosteric modulators, such as calcimimetics (i.e. osteocalcin), are located in the 7-TM region, 
possibly representing a retained (cryptic) ligand binding site in the classical GPCR region. Pi et al. 
hypothesize that osteocalcin (Ocn) and testosterone (T) are also allosteric activators of GPRC6A with 
mechanism of activation similar to calcimimetics because they require the presence of a threshold 
concentration of Ca2+ for signaling to occur. (modified from Pi et Quarles., 2012a) 
GPRC6A receptor has structure/functional characteristics that permit it to sense 
dissimilar ligands. VFTM and 7-TM domains of GPRC6A receptor creates, in fact, the 
structural basis for both independent biological and pharmacological actions of 
orthosteric ligands and allosteric modulators with different affinities and efficacies;  
VFTM and 7-TM domains supports also for the possible cooperative interactions 
between the orthosteric and allosteric ligand binding sites (Figure 5). Accordingly, 
ample evidence exists for the involvement of GPRC6A receptor in the regulation of 
biological processes in humans.  
GPRC6A receptor is physiologically activated by L-α-amino acids, with a preference 
for the naturally occurring basic amino acids Arg, Lys and ornithine (Kuang et al., 
2005; Wellendorph et al., 2005). Interestingly, depending on which signaling 
pathway is studied, the receptor is also positively modulated (Christiansen et al., 
2007; Kuang et al., 2005), or directly activated (Pi et al., 2005) by divalent cations. 
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The broad ligand recognition, and the previously described wide tissue expression, 
have obscured the elucidation of the physiological function of the GPRC6A receptor. 
The generation of Gprc6a-/- mice elucidated potential physiological roles, including 
severe metabolic and endocrinological disturbances (Oury et al., 2011; Pi et al., 
2008; Wellendorph et al., 2009). Interestingly, large discrepancies have been 
observed between different Gprc6a-/- mice of two separate laboratories (Pi et al., 
2008; Wellendorph et al., 2009). Pi et al. reported the previously described 
Osteocalcin-/--like phenotype, feminization of male mice, and decreased bone 
mineral density and impaired mineralization (Pi et al., 2008). Whereas, Wellendorph 
et al. found mice were viable and fertile, developed normally and exhibited no 
significant differences in body weight or skeletal manifestations compared with their 
wild-type littermates. (Wellendorph et al., 2009). 
Given the known physiological importance of the CaR receptor as a metabolic 
regulator (Tfelt-Hansen et Brown, 2005), the phenotype of Gprc6a-/- mice (Pi et al., 
2008), the ability of GPRC6A to mediate osteocalcinin-induced insulin release in vivo 
(Pi et al., 2011), and the novel role of osteocalcin (Lee et al., 2007), it is tempting to 
speculate that GPRC6A receptor could also be implicated in regulation of energy 
metabolism. However, given the wide expression of this receptor, the question 
remains how osteocalcin functions as a cell-specific ligand of GPRC6A receptor. 
Perhaps a co-receptor is required for tissue specificity, as seen for FGF‑23 (another 
bone-derived factor) and its co-receptor, Klotho (Urakawa et al., 2006).  
Osteocalcin in metabolic and cardiovascular diseases 
Clinical studies show  that osteocalcin is involved in glucose homeostasis and 
cardiovascular diseases in humans are small in number and limited in size, but there 
are some evidence supporting a correlation with indicators of metabolic phenotype 
and cardiovascular risk factors.  
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The levels of circulating osteocalcin have mainly be reported to be inversely 
associated with measures of glycemia in cross-sectional studies of nondiabetic 
adults and children, consistent with the hypothesis that osteocalcin influences β‑cell 
function and insulin sensitivity (Lee et al., 2007) (Table 1). Interestingly, in 
prospective analyses, exposure to higher osteocalcin levels during follow-up was 
associated with a significantly lower rise in fasting glucose at 3 years (Pittas et al, 
2009).  
Description of association with osteocalcin N of Subjects Reference 
Inverse with HOMA-IR, fasting glucose and insulin 2493 adults; M + F Saleem et al., 2010 
Inverse with HOMA-IR, fasting glucose 1597 adults; M Iki et al., 2012 
Inverse with HOMA-IR 580 adults; M + F Gravenstein et al., 2011 
Inverse with HOMA-IR, fasting glucose and insulin 380 adults; M + F Pittas et al., 2009 
Inverse with HOMA-IR and fasting glucose 348 adults; M + F Shea et al., 2009 
Inverse with fasting glucose 64 adults; M + F Iglesias et al., 2011 
Table 1. Cross-sectional association between osteocalcin and glucose metabolism in nondiabetic 
adults. F, females; HOMA-IR, Homeostasis Model of Assessment - Insulin Resistance; M, males; 
osteocalcin, total osteocalcin. Only significantly statistically (P < .05) associations are reported. 
Fernandez-Real et al. reported a positive association between insulin sensitivity and 
osteocalcin in a cross-sectional study of 149 lean adult men (Fernandez-Real et al., 
2009), and other did not find any association, like in our cohort of 83 male adults 
patients between osteocalcin and fasting glucose and insulin (Foresta et al., 2010) 
Most of the cross-sectional studies with cohort of nondiabetic children showed no 
association with Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR) 
and fasting insulin (Misra et al., 2007; Pollock et al. 2011; Boucher-Berry et al., 
2012).  
Since the 80s human studies reported that osteocalcin were lower in patients with 
established diabetes and microangiopathic complications (Pietschnann et al., 1988). 
Recently, Im et al. studied glucose metabolism and osteocalcin in 339 
17 
 
postmenopausal Japanese women (Im et al., 2010). Circulating osteocalcin was 
significantly lower among patients with type 2 diabetes when compared to patients 
without diabetes and showed an inverse relationship with fasting glucose, 
glycosylated haemoglobin (HbA1c), and HOMA-IR (Im et al., 2010). A multivariate 
analysis adjusting for age and body weight revealed circulating osteocalcin as an 
independent predictor for glucose and HbA1c levels. Concurrently, an interim 
analysis of the large-scale prospective Fenofibrate Intervention and Event Lowering 
in Diabetes (FIELD) trial (Keech et al., 2005; Sullivan et al., 2011), which included 661 
patients with diabetes mellitus revealed lower fasting glucose, insulin, and HOMA-IR 
levels with increasing levels of circulating osteocalcin (Sullivan et al., 2011). HbA1c 
(7.10 vs. 6.4%) declined substantially from the lowest to the highest tertile of 
osteocalcin in the same population (Sullivan et al., 2011).  
Circulating osteocalcin seem to be inversely associated with measures of adiposity, 
such as percentage body fat and body max index (BMI) (Table 2), despite in our 
cohort of 83 male obese and overweight we did not find any association (Foresta et 
al., 2010).  
Description of association with osteocalcin N of Subjects Reference 
Inverse with and BMI 2493 adults; M + F Saalem et al., 2010 
Inverse with % body fat (only in F) 443 adults; M Shea et al., 2010 
Inverse with % body fat 307 adults; M + F Pitroda et al., 2009 
Inverse with % body fat and BMI 380 adults; M + F Pittas et al., 2009 
Inverse with % body fat and BMI 106 child; M + F Boucher-Berry et al., 2012 
Inverse with visceral fat 86 adults; M Kim et al., 2010 
Table 2. Cross-sectional association between osteocalcin and measures of adiposity in nondiabetic 
adults and children. F, females; BMI, body max index; M, males; osteocalcin, total osteocalcin. Only 
significantly statistically (P < .05) associations are reported. 
Fernandez-Real et al. showed that change in visceral fat was the best predictor of 
change in osteocalcin after controlling for age, BMI, and change in insulin sensitivity 
(P = .002) (Fernandey-Real et al., 2009). A subsequent study from the same group 
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used an hypocaloric diet to achieve weight loss of –22.3 ± 2.3% and a decline in BMI 
of 30.9 ± 5.2% (Fernandez-Real et al., 2010). These changes were accompanied by a 
doubling of circulating osteocalcin from 2.8 ± .75 at baseline to 5.9 ± .9 ng/mL and a 
substantial improvement in HOMA-IR at closeout. 
Bae et al. showed that in patients with a multifactorial pathology like metabolic 
syndrome, osteocalcin was independently associated to its presence (Bae et al., 
2012), according to Saleem et al. observations (Saleem et al., 2010). 
The discrepancies of results from the different studies can be ascribed to multiple 
factors as it is the regulation of osteocalcin synthesis and catabolism and the one of 
energy metabolism. Osteocalcin has been reported to vary by age, sex, smoking 
status, and physical activity (Nimptsch et al., 2007). Unfortunately, most studies di 
not include independent measures of bone formation and resorption, and vitamin K 
status, which limits our ability to address the question of whether osteocalcin acts as 
a mediator or marker. Moreover, cohorts with different pathologies have often been 
included.  
An important point is also the paucity of studies that have measured 
undercarboxylated osteocalcin critically considering possible relationships with the 
etiology of the pathologies of the population,  and possible confounding factors. 
Ueland et al. observed a strongly increase in total and undercarboxylated 
osteocalcin levels in acromegalic patients when compared to healthy controls, but 
only total osteocalcin was a significant independent predictor of the HOMA-IR index 
(Ueland et al., 2010). Ferron et al. showed that patients with osteopetrosis had an 
increased ratio of undercarboxylated osteocalcin to carboyalated osteocalcin, 
accompanied by markedly low insulin levels (Ferron et al., 2010). Kanazawa et al. 
showed an increment of total osteocalcin by 90%, while undercarboxylated 
osteocalcin exhibited a non-significant rise of only 17% in 50 poorly controlled 
diabetics study during a month of intensified glycemic control (Kanazawa et al., 
2009a). The same group has subsequently extensively described in diabetic patients 
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the previous data, overall showing total and undercarboxylated osteocalcin were 
inversely associated with fasting glucose and visceral fat, and positively with serum 
adiponectin level, parameters of insulin secretion, and its sensitivity in humans 
(Kanazawa et al., 2009b; Kanazawa et al., 2011a; Kanazawa et al., 2011b). Moreover, 
Kanazawa et al. showed an association between osteocalcin and atherosclerosis in 
diabetic patients (Kanazawa et al, 2009b), in agreement with the observation of 
Pietschnann et al. (Pietschnann et al., 1988). Our group showed that  
undercarboxylated osteocalcin to total osteocalcin ratio was negatively correlated to 
body mass index (ρ = .233; P ≤ .05) in a cohort of 83 patients; undercarboxylated 
osteocalcin was negatively correlated with waist circumference (ρ = .362; P ≤ .05) 
and fasting glucose (ρ =  .430; P ≤ .05) in the overweight and obese group, 
suggesting the importance of the excess of the adipose tissue and the associated 
possible hypogonadsim (Foresta et al., 2010).  
The poor association between undercarboxylated osteocalcin and glucose 
metabolism in humans contrasts with findings in mouse models. If osteocalcin, but 
not its undercarboxylated form, it is inversely correlated with glucose metabolism 
and adiposity in humans, and becomes important to discern if osteocalcin is 
mediating this effect or if it is an independent indication of an impaired osteoblast, 
as suggested by studies in an insulin-resistant rat model of diabetes mellitus 
(Hamann et al., 2011).  However, the low number of studies that directly measured 
both the total and the undercarboxylated forms of osteocalcin, precludes forming 
conclusions regarding the importance of osteocalcin carboxylation in glucose 
metabolism. Similarly, very few studies used assays that measure the percentage of 
undercarboxylated osteocalcin, which would address any concern related to the 
strong correlation between total and undercarboxylated osteocalcin concentrations. 
Finally, it is likely that the association with osteocalcin in its different γ-carboxylated 
forms can differ between cohorts due to the different etiologies, but this 
observation also highlight the importance of other modulating co-factors. 
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Endogenous sex steroid hormones in metabolic and cardiovascular 
diseases 
Testosterone (T) and other endogenous sex hormones are important signaling 
molecule in regulating energy metabolism. Testosterone is known to have a role in 
glucose homeostasis as well as obesity and lipid metabolism (Pi et al., 2010; Pi et 
Quarles, 2012a). This suggests that testosterone deficiency (i.e. hypogonadism) may 
contribute to the etiology of obesity, metabolic syndrome and its sequels, namely 
type 2 diabetes mellitus and other cardiovascular diseases. Low testosterone 
concentrations were associated with a higher incidence of type 2 diabetes mellitus 
in men, with the converse seen in women. A systematic review and meta-analysis 
including 36 cross-sectional and 7 prospective studies reported a significantly lower 
testosterone concentration in men with type 2 diabetes mellitus (-2.7 nmol/L, 95% 
CI -3.4 to -1.9 nmol/L). Men with a higher testosterone concentration (>15.6 nmol/L) 
had a 42% lower risk of type 2 diabetes mellitus (relative risk .58, 95%CI .39-.87) 
(Ding et al., 2006). 
Epidemiological evidence associate additional biological significance to the principal 
transport protein for sex steroid hormones, the sex hormone binding globulin 
(SHBG). Low SHBG concentration were associated with increased risk of 
development of type 2 diabetes mellitus. Two genetic studies demonstrated an 
association between three SNPs, SHBG concentration and the incidence of type 2 
diabetes mellitus, suggesting that the relationship between SHBG and the risk of 
developing diabetes may well be causal (Ding et al., 2006; Ding et al., 2009; Perry et 
al., 2010; Le et al., 2012).  
Multiple factors and unraveled hormones may confound the association between 
endogenous sex hormones, energy metabolism and bone, including age, gender, 
obesity, body composition, osteocalcin, and risk factors of metabolic and 
cardiovascular diseases. 
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Figure 5. Potential mechanisms for the relationship between sex hormone binding globulin (SHBG) 
and type 2 diabetes mellitus. Alterations in SHBG may contribute to derangements in glucose 
homeostasis through modulation of sex hormone bioavailability. Recent findings also support a 
specific SHBG receptor, implying a more direct role of the protein in certain intracellular signaling 
pathways. Aside from influencing sex-steroid bioavailability, decreases in SHBG, either directly or via 
SHBG receptor activation, may have hypothetical effects (represented by dotted lines) that increase 
insulin resistance and reduce β cell function leading to glucose intolerance and ultimately overt 
diabetes. RSHBG, SHBG receptor. (modified from Le et al., 2012) 
Osteocalcin and endogenous sex steroid hormones: a common 
receptor? 
Osteocalcin and endogenous sex hormones appear to potentially share a common 
receptor, GPRC6A receptor.  
GPRC6A appears to mediate the non-genomic effects of testosterone as evidence by 
the loss of the rapid signaling responses to testosterone administration in Gprc6a-/-
mice (Pi et al., 2010). Testosterone also has rapid effects on insulin secretion in β -
cells (Grillo et al., 2005), which also appear to be mediated through activation of 
GPRC6A receptor (Pi et al., 2010). Thus, testosterone may have both effects on 
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insulin sensitivity as well as a direct effect on insulin secretion that are at least 
partially mediated via GPRC6A receptor (Pitteloud et al. 2005). 
SHBG has an own receptor, but it has not been cloned yet. Hryb et al. showed that 
SHBG bound to human prostatic cell membranes with high specificity and affinity  
(Hryb et al., 1985). The specific binding of SHBG to cell membranes has been 
demonstrated in a limited number of tissues, including endometrium, breast cancer 
cells, normal breast, prostate, proximal convoluted tubule cells of the kidney, liver 
and epididymis (Rosner et al., 2010), thus making the interaction reasonably specific 
to tissues that are responsive to the steroids which bind to SHBG. SHBG receptor is 
thought to be a G protein-coupled receptor. Activation of the G protein-coupled 
second messenger system leads to release of cAMP and then to activation of protein 
kinase A (PKA) (Nakhla et al., 1999). 
Osteocalcin from mouse to human 
Overall, some translational data support the notion that osteocalcin activity is 
determined in humans in a similar way that in mice, highlighting the importance of 
the γ -carboxylation status of Glu residues for structure and function. Moreover, no 
molecule identified as a hormone in the mouse has lost this function in humans. 
However, the strength and reciprocity of the interactions and their physiological 
relevance in humans remain to be explored, clarifying the inconsistencies that has 
emerged from the current literature and the known physiology of the two different 
species.  
We reported previously how human Osteocalcin is encoded by a single-copy gene. 
Mice have a cluster of three Osteocalcin genes in a 23 kb span oriented in the same 
transcriptional direction. Two of the genes (Bglap and Bglap2, also known as OG1 
and OG2) are expressed only in bone, while the third, the osteocalcin-related gene 
(Bglap-rs1, also known as ORG), is expressed at low levels in brain, lung and kidney, 
but not in bone (Desbois et al., 1994). Examination of the promoters of the human 
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and rat genes reveal that they are very similar with respect to the organization of 
regulatory elements and their response to hormones and growth factors, whereas 
the mouse gene exhibits differences, particularly in response to vitamin D3, the 
formers being dose-dependently up-regulated, whereas the latter being down-
regulated (Kerner et al., 1989; Lian et al., 1989).  
Esp is a pseudogene in humans (Cousin et al., 2004). Ferron et al., starting from the 
identification of the insulin receptor as a substrate of the phosphatase OST-PTP, 
hypotesized that tyrosine-protein phosphatase nonreceptor type 1 (PTN1, also 
known as PTP-1B, ubiquitously expressed) partially exerts in human the regulatory 
action of OST-PTP, being able to dephosphorylate insulin receptor. OST-PTP in 
mouse seem to regulate insulin signaling in osteoblasts, enhancing osteocalcin 
activity by promoting the ability of osteoblasts to enhance bone resorption and, 
indeed, potentially also in human the osteocalcin decarboxylation due to the 
previously described acid pH in the resorption lacuna (Silver et al., 1988; Ferron et 
al., 2010). Patients with a missense mutation in ClCN7, a gene required for acid 
secretion in the resorption lacuna (Schaller et al., 2005), and in others with a 
decrease of acidification ability of osteoclasts, circulating undercarboxylated 
osteocalcin was significantly decreased in all patients (Ferron et al., 2010). Zee et al. 
demonstrated that another tyrosine-protein phosphatase nonreceptor type 2 (PTN2, 
also known as TC‑PTP) also regulates insulin receptor phosphorylation in human 
osteoblasts and is, in fact, more highly expressed in bone than either OST-PTP or 
PTP-1B (Zee et al., 2012). 
Neither mice osteocalcin cristallographyc structure nor human osteocalcin one have 
been resolved yet. Mouse and human and osteocalcin show extensive amino acid 
sequence homology in the region containing the three Glu residues (i.e. 
EXXXEXCEXXXXC motif), with a different length in total amino acids residues. Frazao 
et al. described possible differences between Gla residues in the 3-D structure of 
osteocalcin from different species (Frazao et al., 2005) (Figure 6). 
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Figure 6. Cartoon representation of the superposition of different types of osteocalcin. A. regius 
molecules A (cyan), B (medium blue), and C (dark blue), with Gla residues positions represented as 
spheres, superpose clearly with the porcine structure (yellow), while the bovine structure (red) shows 
much less secondary structure and a poor match of Gla residues. (modified from Frazao et al., 2005) 
Finally, adult mice do not express SHBG, whereas SHBG concentration have been 
associated in humans with increased incidence of type 2 diabetes (Ding et al., 2006), 
despite the exact nature has still to be elucidate. It is interesting to underline again 
that SHBG have a putative G protein-coupled receptor (Rosner et al., 2010), but the 
details of the molecular mechanism are not elucidated yet. 
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AIM of the STUDY 
The use of mouse genetics recently highlighted coordination by endocrine regulation 
between bone, energy metabolism, and endogenous sex hormones. Osteocalcin, a 
bone matrix protein that regulates hydroxyapatite size and shape through its 
vitamin‑K-dependent γ‑carboxylated form, unraveled endocrinological functions in 
its circulating forms, that are not only simple markers of bone formation. In 
particular, recombinant undercarboxylated osteocalcin administration regulates 
gene expression not only in adipocytes, but also in pancreatic β cells and in Leydig 
cells in animal models, with a potential gender selectivity. Despite that circulating 
concentrations of osteocalcin in humans are inversely associated with measures of 
glucose metabolism, human data are inconclusive regarding the role of different γ-
carboxylated forms of osteocalcin in energy metabolism and endogenous sex 
hormones. Most human studies do not differentiate between total and 
undercarboxylated forms of osteocalcin and do not take into account endogenous 
sex hormones, whose circulating concentration and tissue transport are regulate in a 
species-specific way in humans and mice. Intriguingly, the recently identified 
receptor of osteocalcin (i.e. GPRC6A receptor) is a G protein-coupled receptor that 
mediates also the non-genomic effects of androgens and, although the information 
about SHBG-receptor structure is not conclusive, evidence seems to suggest that a G 
protein-coupled receptor is involved. 
 
Figure 7. Two-step approach to human osteocalcin physiology and unraveled endocrinological 
functions. 
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Starting from clinical observations, we investigated the protein-protein interaction 
computational predictors of osteocalcin and SHBG with GPRC6A receptor, and we 
validated experimentally in vitro in  a two-step approach (Figure 7). 
In particular, due to the lack of data about osteocalcin γ-carboxylated forms, we 
focused on the determinants of osteocalcin structure between its carboxylated and 
uncarboxylated forms, and the effects of Ca2+ binding.  
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MATERIALS and METHODS 
Study subjects 
The study groups consisted of 63 male patients with obesity (BMI ≥ 25 kg/m2), 
referred to the Obesity Clinic of the University of Padova, and 28 age male healthy 
controls (BMI ≥ 18.5–24.9 kg/m2) consecutively recruited. Nobody had hepatic or 
renal failure. All subjects were free from drugs known to influence bone and calcium 
metabolism (e.g. steroids, vitamin D and K, calcitonin, bisphosphonates, and 
thiazolidinediones). All patients underwent physical examination, including 
anthropometric and blood pressure measurement, and a venous blood sample was 
collected after overnight fasting and stored at -80 °C after plasma separation. Our 
institutional review board approved this study and each participant provided 
informed consent. The investigation was conformed to the principles of the 
Declaration of Helsinki. 
Biochemical markers measurements 
Biochemical markers were measured by standard methods. Total testosterone and 
estradiol were measured by a commercial electrochemiluminescence immunoassay 
(Elecsys 2010, Roche Diagnostics, Mannheim, Germany). SHBG was measured by 
chemiluminescence assay (Immulite 2000, Siemens, Milano, Italy). The interassay 
coefficient of variation (CV) was below 10%.  
The value of free T was estimated by calculation from total T and SHBG 
concentrations, which is comparable to free T concentration obtained by equilibrium 
dialysis, except in pregnancy (Vermeulen et al., 1999). Apart from albumin, the only 
other protein that binds T is SHBG. As the binding of other steroid hormones 
normally present in plasma can be omitted from the calculation (Vermeulen, 1973), 
it follows: free T = ([T] - (N x [FT]))/(Kt{SHBG x [T] + N[FT]}) (Eq IV), where Kt is the 
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association constant of SHBG for T, and N = KaCa + 1. This yields a second degree 
equation that can be solved either for free T or SHBG (Vermeulen et al., 1999).  
Carboxylated and undercarboylated osteocalcin were measured in blood serum by 
enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s 
instruction (Takara, Basel, Switzerland). The detection limits of the kit for 
carboxylated osteocalcin were 0.5-16 ng/ml. Inter-assay CV for this kit were 1% and 
2.4% for 12.10 and 0.62 ng/ml cOC, respectively, and the intra-assay CV were 3.3% 
and 4.8% for 12 and 0.60 ng/ml, respectively. The detection limits of the kit for 
undercarboxylated osteocalcin were 0.25–8 ng/ml. Inter-assay CV for this kit was 
5.67% and 9.87% for 6.47 and 0.69 ng/ml for ucOCN, and the intra-assay CV were 
4.6% and 6.7% for 6.87 and 0.79 ng/ml, respectively. Total osteocalcin was 
estimated as the sum of the carboxylated osteocalcin and undercarboxylated forms 
of osteocalcin. ucOC/OC ratio was used as one of the parameters.  
Others biochemical markers, including fasting blood glucose, insulin, C-peptide, and 
leptin, were measured by standard biochemical methods. All measurements were 
performed in duplicate.  
Protein sequence alignment analysis 
It has been postulated that the native tertiary structure of a given protein is 
determined solely by the protein’s amino acid sequence in a given environment 
(Anfinsen, 1973), and that proteins with similar sequences adopt similar structures 
(Chothia et Lesk, 1986). Conserved structural domains can originate from sequences 
with less than 12% sequence identity (Holm et Sander, 1996; Hubbard et al., 1997; 
Rost, 1999). Thereafter, comparative methodology started form an approach 
involving a primary structure alignment through NW-align algorithm.  
NW-align (http://zhanglab.ccmb.med.umich.edu/NW-align/) is a simple and robust 
alignment program based on the standard Needleman-Wunsch dynamic 
programming algorithm for the prediction of homologue surface motives and 
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clusters  of amino acids, owning to protein predicted interactions (Needleman et 
Wunsch, 1970). An alignment of two sequences is represented by three lines. The 
first line shows the first sequence, and the third line shows the second sequence. 
The second line has a row of symbols. The symbol is a vertical linking simbol where 
ever characters in the two sequences match, and a space where ever they do not. 
Dots may be inserted in either sequence to represent gaps.  
The algorithm was applied between SHBG and osteocalcin, whose primary 
sequences were obtained from UniPROTKB/Swiss-Prot (O'Donovan et al., 2002; 
Bairoch et al., 2004). In particular, sequence of osteocalcin  precursor 
(UniProtKB/Swiss-Prot entry P02818.2) were:  
MRALTLLALLALAALCIAGQAGAKPSGAESSKGAAFVSKQEGSEVVKRPRRYLYQWLGAPVPYPDPLEP
RREVCELNPDCDELADHIGFQEAYRRFYGPV 
and sequence of SHBG precursor (UniProtKB/Swiss-Prot entry P04278.2) was: 
MESRGPLATSRLLLLLLLLLLRHTRQGWALRPVLPTQSAHDPPAVHLSNGPGQEPIAVMTFDLTKITKTSS
SFEVRTWDPEGVIFYGDTNPKDDWFMLGLRDGRPEIQLHNHWAQLTVGAGPRLDDGRWHQVEVKMEG
DSVLLEVDGEEVLRLRQVSGPLTSKRHPIMRIALGGLLFPASNLRLPLVPALDGCLRRDSWLDKQAEISAS
APTSLRSCDVESNPGIFLPPGTQAEFNLRDIPQPHAEPWAFSLDLGLKQAAGSGHLLALGTPENPSWLSLH
LQDQKVVLSSGSGPGLDLPLVLGLPLQLKLSMSRVVLSQGSKMKALALPPLGLAPLLNLWAKPQGRLFL
GALPGEDSSTSFCLNGLWAQGQRLDVDQALNRSHEIWTHSCPQSPGNGTDASH 
3-D protein structure alignment analysis  
An approach with four different algorithms for three dimensional (3-D) alignments 
was used to recognize possible alignments between the query and the target 
structures, based on different criteria (Figure 8). 
 
Figure 8. 3-D protein structure alignment analysis workflow between SHBG and osteocalcin (OC). 
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TM-align (http://bioinformatics.buffalo.edu/TM-align) is a structural alignment 
algorithm to identify the best structural alignment between protein pairs that 
combines the TM-score rotation matrix and Dynamic Programming (DP) (Zhang et 
Skolnick, 2005). The TM-score, in particular, (Zhang et Skolnick, 2004) weights the 
residue pairs at smaller distances relatively stronger than those at larger distances, 
exploiting a variation of Levitt–Gerstein (LG) weight factor (Levitt et Gerstein, 1998), 
implementing the root-mean-square deviation (RMSD). An optimal alignment 
between two proteins, as well as the TM-score value, will be reported for each 
comparison. TM-align can be used to match the predicted models for solved non-
homologous proteins in the Protein Data Bank (PDB). For both folded and mis-folded 
models, TM-align can almost always find close structural analogs, with an average 
RMSD of 3 Ȧ and 87% alignment coverage, whose data are given in the final output. 
The value of TM-score lies in between 0 to 1. In general, a comparison of TM-score < 
0.2 indicates that there is no similarity between two structures; a TM-score > 0.5 
means the structures share the same fold. 
Flexible structure AlignmenT by Chaining Aligned Fragment Pairs (FATCAT, 
http://fatcat.burnham.org/) is a an algorithm that allows structural alignment of 
proteins, simultaneously addressing the two major goals of flexible structure 
alignment: (i) optimizing the alignment and (ii) minimizing the number of rigid-body 
movements (twists) around pivot points (hinges) introduced in the reference protein 
(Ye et Godzik, 2003). Therefore, it avoids the problem of existing flexible structure 
alignment programs that separate these two goals, such as introducing too many 
hinges into the alignment or missing the optimal alignment because of significant 
errors in the initial rigid-body alignment of structure obtained by X-ray 
crystallography. In particular, the structure alignment is formulated as the AFPs 
chaining process allowing at most t twists, and the flexible structure alignment is 
transformed into a rigid structure alignment when t is forced to be 0. Moreover, a 
dynamic programming is used to find the optimal chaining. A final chaining score is 
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given, including information regarding  RMSD (dk), length (L), mis-matched regions 
(p) and/or gaps (q), and the required number of  twists T(k). 
TriangleMatch (http://bioinfo3d.cs.tau.ac.il/TriangleMatchBeta/index.html) is an 
algorithm designed to find non-topographical, sequence independent similarities 
between protein structural motifs, suitable for quick scanning of structural data 
bases (Nussinov et Wolson, 1991). The method is truly 3-D, sequence-order 
independent, and thus insensitive to gaps, insertions, or deletions. This algorithm is 
based on the geometric hashing paradigm, which allows the program to find 
structural matches that are independent of the amino-acid reside sequence. The 
algorithm used finds, in particular, pairs of sub-structures from the two proteins that 
after under-going a rigid transformation will give the largest match possible. The 
algorithm uses protein structures, atomic labels, and the respective 3-D coordinates; 
protein's backbones are structurally compared using their Cα atoms coordinates. A 
set of high scoring conformations, whose P value is based on results of an all-
against-all matching of superfamilies representatives, is output and the user may 
view these conformations in a PDB file viewer. The number of best matches can be 
set and are shown by score, and secondarily by RMSD.  
TopMatch (http://services.came.sbg.ac.at) is not only a computational algorithm for 
protein structure alignment, but also for the visualization of structural similarities, 
and for highlighting relationships found in protein classifications (Sippl et 
Wiederstein, 2008). Given a pair of protein structures, TopMatch calculates a ranked 
list of alignments based on the computing of a sequence score using a structure 
derived substitution matrix (Prlic et al., 2000). The alignments are characterized by a 
small set of parameters, including again the length of an alignment  and the absolute 
similarity S(q,t). Additional useful parameters are the root-mean-square error of 
superposition (RMES), percentage of sequence identity (Identity), the relative 
similarity s(q,t)= 100 x 2S(q,t)/(Lq+Lt), and the relative query and target cover 
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defined as cq=100 x S(q,t)/Lq and ct=100x S(q,t)/Lt, respectively (here Lq and Lt are 
the respective sequence lengths).  
Protein docking analysis 
A computational prediction of the 3-D structures of molecular interactions was 
retrieved to produce structural predictions with atomic-level accuracy. The use of 
protein docking to distinguish binding versus non-binding proteins is based on 
docking scores (Wass et al., 2011). Protein docking analysis and detailed 
comparative analyses of the performance of different docking algorythms (Wang et 
al. 2003) demonstrate the dependence of docking accuracy on the conformational 
search methods, the quality of the protein-ligand potentials describing binding 
enthalpy, and the scoring methods for estimation of protein-ligand binding entropy. 
Both osteocalcin and SHBG with the putative plasma membrane receptors in target 
tissues of osteocalcin (i.e. GPRC6A receptor), underwent to a molecular docking 
approach. 
Sequence of GPRC6A receptor from Swiss-Prot database (UniProtKB/Swiss-Prot 
entry Q5T6X5.1) was: 
MAFLIILITCFVIILATSQPCQTPDDFVAATSPGHIIIGGLFAIHEKMLSSEDSPRRPQIQECVGFEISVFLQTL
AMIHSIEMINNSTLLPGVKLGYEIYDTCTEVTVAMAATLRFLSKFNCSRETVEFKCDYSSYMPRVKAVIGS
GYSEITMAVSRMLNLQLMPQVGYESTAEILSDKIRFPSFLRTVPSDFHQIKAMAHLIQKSGWNWIGIITTD
DDYGRLALNTFIIQAEANNVCIAFKEVLPAFLSDNTIEVRINRTLKKIILEAQVNVIVVFLRQFHVFDLFNK
AIEMNINKMWIASDNWSTATKITTIPNVKKIGKVVGFAFRRGNISSFHSFLQNLHLLPSDSHKLLHEYAMH
LSACAYVKDTDLSQCIFNHSQRTLAYKANKAIERNFVMRNDFLWDYAEPGLIHSIQLAVFALGYAIRDLC
QARDCQNPNAFQPWELLGVLKNVTFTDGWNSFHFDAHGDLNTGYDVVLWKEINGHMTVTKMAEYDL
QNDVFIIPDQETKNEFRNLKQIQSKCSKECSPGQMKKTTRSQHICCYECQNCPENHYTNQTDMPHCLLCN
NKTHWAPVRSTMCFEKEVEYLNWNDSLAILLLILSLLGIIFVLVVGIIFTRNLNTPVVKSSGGLRVCYVILL
CHFLNFASTSFFIGEPQDFTCKTRQTMFGVSFTLCISCILTKSLKILLAFSFDPKLQKFLKCLYRPILIIFTCTG
IQVVICTLWLIFAAPTVEVNVSLPRVIILECEEGSILAFGTMLGYIAILAFICFIFAFKGKYENYNEAKFITFG
MLIYFIAWITFIPIYATTFGKYVPAVEIIVILISNYGILYCTFIPKCYVIICKQEINTKSAFLKMIYSYSSHSVSSI
ALSPASLDSMSGNVTMTNPSSSGKSATWQKSKDLQAQAFAHICRENATSVSKTLPRKRMSSI 
Previous studies developed homology model of the trans-membrane bundle of 
GPRC6A receptor from the group-to-group alignment against the crystallized 
sequences of both β1 and rhodopsin as templates (Pi et al., 2010) using MOE 
33 
 
(Chemical Computing Group, Montreal, Canada) software. We chose an homology 
model for the isoform 1 of GPRC6A receptor form MODBASE database, developed 
on the crystallographic structure of a metabotropic glutamate receptor (mGluR-II3) 
(Pieper et al., 2004; Muto et al., 2007), due to Family identity reasons. 
An approach with three different algorithms for 3D alignments for Protein docking 
analysis was used to recognize a possible relationships between the query and the 
target (Figure 9), according to the work-flow explained in the “3-D protein structure 
alignment analysis” section. 
 
Figure 9. Protein docking analysis workflow between GPRC6A and SHBG/osteocalcin (OC). 
GRAMM-X protein docking algorithm 
(http://vakser.bioinformatics.ku.edu/resources/gramm/grammx) is an extention of 
the original Global RAnge Molecular Matching (GRAMM) Fast Fourier 
Transformation (FFT) methodology (Tovchigrechk et Vakser, 2006). GRAMM-X 
requires only the atomic coordinates of the two molecules To predict the structure 
of a complex (no information about the binding sites is needed). The program 
performs an exhaustive 6-D search through the relative translations and rotations of 
the molecules. The quality of the prediction depends on the accuracy of the 
structures. The GRAMM methodology use an empirical approach to smoothing the 
intermolecular energy function by changing the range of the atom-atom potentials, 
locating the area of the global minimum of intermolecular energy for structures of 
different accuracy with a correlation technique based on the so called FFT 
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(Katchalski-Katzir et al., 1992). GRAMM-X has been implemented by employing 
smoothed potentials, refinement stage, and knowledge based scoring.  
ZDOCK (http://zdock.umassmed.edu/ ) is a protein docking algorithm using FFT to 
perform a 3-D search of the spatial degrees of freedom between two proteins 
(Pierce et al., 2011). ZDOCK searches all possible binding modes in the translational 
and rotational space between the two proteins, and evaluates each by an energy 
scoring function, including shape complementarity, electrostatics, and a pairwise 
atomic statistical potential. In particular, utilizing a pairwise atomic potential, ZDOCK 
has notably gained in docking accuracy. Finally, the incorporation of the 3-D 
convolution library into ZDOCK, and the additionally modified ZDOCK to dynamically 
(e.g. optimal centering of the input proteins, rotation of the receptor, switching of 
the ligand and receptor) has oriented the input proteins for more efficient 
convolution. Interestingly, search speed is greatly increased by converting each 
protein's structure to a digital signal. 
PatchDock (http://bioinfo3d.cs.tau.ac.il/PatchDock/patchdock.html) is a geometry-
based molecular docking algorithm. It is aimed at finding docking transformations 
that yield good molecular shape complementarity (Schneidman-Duhovny  et al. 
2005). Such transformations, when applied, induce both wide interface areas  and 
small amounts of steric clashes. A wide interface is ensured to include several 
matched local features of the docked molecules that have complementary 
characteristics. The PatchDock algorithm divides the Connolly dot surface 
representation of the molecules into concave, convex and flat patches (Stage I, 
Molecular Shape Representation) (Connolly, 1983). Thereafter, the complementary 
patches are matched in order to generate candidate transformations employing a 
hybrid of the Geometric Hashing and Pose-Clustering matching techniques (Stage II, 
Surface Patch Matching). Each candidate transformation is further evaluated by a 
scoring function that considers both geometric fit and atomic desolvation energy 
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(Stage III, Filtering and Scoring) (Zhang et al., 1997). Finally, an RMSD clustering is 
applied to the candidate solutions to discard redundant solutions.  
The docking output analysis, presenting the series of top solutions of  the predicted 
interactions between proteins, underwent to a comparative analysis between the 
frequencies of the predicted interfaces between SHBG and GPRC6A receptor, their 
spatial position in SHBG crystallographic structure and the similarity to osteocalcin, 
supported by PDBePISA (European Bioinformatics Institute©). PDBePISA 
(http://www.ebi.ac.uk/msd-srv/prot_int/) is an interactive tool for the exploration 
of macromolecular (protein, DNA/RNA and ligand) interfaces, prediction of probable 
quaternary structures (assemblies), database searches of structurally similar 
interfaces and assemblies, as well as searches on various assembly and PDB entry 
parameters.  
Molecular modeling studies 
Homology molecular modeling is a computational approach to predict the 
approximate tertiary structure (3-D) of a protein based on the known 3-D structure 
of a closely related protein.  
The protein model is performed in four steps (Schwede et al. 2003), including: 
1. Structural template selection (at least one known protein structure protein); 
2. Alignment of template and target sequences; 
3. Model building (protein backbone assignment, placing and energy 
minimization of side-chain conformations); 
4. Model evaluation of protein geometry with respect to sterical hindrance, 
potential energy (dihedral angles, angles, bond-length and electrostatic 
interactions). 
The structure of the human osteocalcin was carried out using a conventional 
homology modeling approach implemented in MOE (Chemical Computing Group, 
Montreal, Canada; version 2010.11) software (http://www.chemcomp.com) and 
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using porcine osteocalcin as a structural template, having 88% sequence identity 
with human osteocalcin (Protein Data Bank entry 1Q8H) (Hoang et al., 2003).  
Hydrogen atoms and electric charges were added using the “Protonate-3D” tool 
implemented in MOE. To minimize contacts among hydrogens, the structures were 
subjected to Amber94 force field minimization (Okur et al., 2003; Ponder et Case, 
2003) until the rms of conjugate gradient was <0.1 kcal/mol/Å, keeping heavy atoms 
fixed at their crystallographic positions. Model quality was evaluated using the MOE 
Protein Geometry stereochemical quality evaluation tools. 
Molecular dynamics studies 
tLeap (Case et al., 2005) and Amber FF99SB (Hornak et al., 2006) were employed for 
the parametrization of the  protein models osteocalcin in different γ-carboxylated 
forms. Gla residues were parameterized “from scratch” using molecular information 
from the available crystal structures, while Ca2+-ions were parameterized as 
previously detailed (Bradbrook et al., 1998). The protein models were equilibrated in 
TIP3P water boxes and finally added counterions (e.g., Na+) to assure the neutrality 
of the molecular systems. ClickMD-min script (Cristiani et al., 2011) was used as a 
molecular dynamic platform for minimizing Gla and Glu osteocalcin structures in 
Ca+2-bound form. ClickMD-min uses NAMD 2.7b3 as MD engine and produced 
100,000 steps of conjugated-gradient minimization using a 32 cores Intel Core2Quad 
Q9600 2.66Ghz. ClickMD-eq script was used for equilibrating the protein models and 
their solvatation systems (0.5 ns, Cα positional restrains), while ClickMD-prod was 
employed to simulate large-scale MD for 100 ns in osteocalcin systems in the 
presence of Ca2+ (100 ns NVT, P=1atm, T=300K). Analysis of trajectories was 
performed with VMD 1.8.7 (Humphrey et al., 1996), RMSD Trajectory Tools 2.01 
(http://physiology.med.cornell.edu/faculty/hweinstein/vmdplugins/rmsdtt/), 
RAINBOWRMSD and NRGPLOT (Cristiani et al., 2011). 
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Steered molecular dynamics studies 
Steered molecular dynamics (SMD) was performed with YASARA (Krieger et al. 2002: 
Krieger et al., 2006) applying a constant pulling acceleration of 35,000 pm/ps2 on the 
Ca2+ ions. The pulling direction of the acceleration is represented by the distance 
between the centre of mass of the protein and the respective ion. SMD simulations 
of 50 ps has been repeated three times after the assignment of different initial atom 
velocities to each molecular system, highlighting converging results. 
Spectroscopic techniques 
Human Gla osteocalcin and murine Glu osteocalcin were purchased form Bachem 
(Bachem AG, Bubendorf, Switzerland) and their purity and chemical identity was 
checked by reverse phase high-performance liquid chromatography (RP-HPLC) and 
mass spectrometry. An aliquot (20 μg) of osteocalcin was loaded onto a Vydac C18 
column (4.6 × 250 mm, 5 μM) (Hesperia, CA, USA) eluted with an acetonitrile 0.078% 
TFA gradient from 20 to 60% in 30 min at the flow rate of 0.8 ml/min. Mass 
spectrometry analysis was carried out on a Mariner (PerSeptive Biosystems, 
Stafford, TX, USA) ESI-TOF spectrometer, yielding mass values in agreement with 
theoretical mass within 50 ppm accuracy. Binding of Ca2+ to Gla osteocalcin or Glu 
osteocalcin was studied by fluorescence and circular dichroism (CD) spectroscopy. 
Aliquots (2-50 μl) of a CaCl2 stock solution (150 mM) were added under gentle 
magnetic stirring to a solution of OC (1.5 ml; 1 μM) in a 1-cm pathlength quartz 
cuvette for fluorescence measurements. All measurements were carried out in 20 
mM Tris-HCl, pH 7.4, at 25 ± 0.2 °C on a Jasco (Tokyo, Japan) FP-6500 
spectrofluorimeter equipped with a Peltier temperature control system ETC-273T. 
Samples were excited at 280 nm and the emission intensity was recorded at 344 nm, 
using an excitation emission slit of 5/10 nm. Each spectrum was the average of two 
accumulations after baseline subtraction.  
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Aliquots (2-50 μl) of a CaCl2 stock solution (150 mM) were added under gentle 
magnetic stirring to a solution of OC (1.5 ml; 20 μg/ml) in a 1-cm pathlength cuvette 
for CD measurements. Ellipticity data (θ) at 220 nm are expressed as millidegrees 
without further normalization. All measurements were carried out in 20 mM Tris-HCl 
at pH 7.4 and 25 ± 0.2 °C on a J-810 spectropolarimeter equipped with a Peltier 
temperature control system PTC-423S. Each spectrum was the average of four 
accumulations, after base line subtraction. Data points were fitted using the 
equation: 
θ = θ0+[θmax∙([Ca+2]/Kd))/(1+[Ca+2]/Kd)      
  (eq. 1) 
where θ0 and θmax are the ellipticity values of OC in the absence and at saturating 
calcium concentration, respectively, and Kd is the dissociation constant of the 
complex Ca2+-osteocalcin. 
Cell line HEK-293T  
The human kidney cell line 293 was generated by transfection of adenovirus DNA 
into normal human embryonic kidney (HEK) cells (Graham et al., 1977), whereas the 
human kidney cell lines STt-4i (293T) were generated by transfection of HEK cells 
with plasmids encoding SV40 viral oncogene (Robinson et al., 1991). In the initial 
seed stock at the American Type Culture Collection, ATCC (Manassas, VA, USA), 
HEK293 was described as an hypotriploid human epithelial cell line.  The modal 
chromosome number was 64, occurring in 30% of cells. The rate of cells with higher 
ploidies was 4.2%. The der(1)t(1;15) (q42;q13), der(19)t(3;19) (q12;q13), 
der(12)t(8;12) (q22;p13), and four other marker chromosomes were common to 
most cells. There were four copies of N17 and N22. Noticeably in addition to three 
copies of X chromosomes, there were paired Xq+, and a single Xp+ in most cells. 
However, cytogenetic instability has been reported in the literature for some cell 
lines. 
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HEK-293T were cultured in 75 cm2 cell culture flasks with ATCC-formulated 
Dulbecco's Modified Eagle's Medium, adding  fetal bovine serum to a final 
concentration of 10% and 10,000 μg/ml penicillin/streptomycin at  pH 7.7 under an 
air/5% CO2 mixture, as previously described (Aulestia et al., 2011).  
RNA extraction, cDNA synthesis and RT-PCR 
Total RNA was purified and extracted from cell pellets using the Qiagen RNeasy Mini 
Kit (Quiagen, Germantown, MD, USA).  First strand cDNA synthesis from total RNA 
was catalyzed by SuperScript® III RT using random hexamers, including a 
deoxyribonuclease treatment according to the manufacturer protocol. All isolated 
RNA was quantified by spectrophotometry by determining the ratio of optical 
density at 260/280 nm, using a Nano-Drop® spectrophotometer (Wilmington, DE, 
USA).  
Total cDNA was amplified by PCR using specific primers for each gene to verify cDNA 
presence and quality. As a negative control, cDNA was omitted. 
The primers used to amplify various gene from HEK-293T cells were internally 
designed. The primers were hGprc6a_1 forward 5’-AAGACTCTCCCAGACGACCA-3’ 
and reverse 5’-CTCAATGCTGTGTATCATGGC-3’ (92 bp, exon spanning), hGprc6a_3 
forward 5’-  AAGACTCTCCCAGACGACCA-3’ and reverse 5’-
CATACCCCAGTTTGACTCCAG-3’ (138 bp, exon spanning), and hGprc6a_ART  forward 
5’-CAGGAGTGTGTTGGCTTTGA-3’ and reverse 5’-  AAAGCAATGGCTCACCTGAT-3’ (428 
bp, exon spanning). To control for intact RNA recovery and the uniform efficiency of 
each RT reaction β-actin was amplified by PCR using after primers, including forward 
5′-CACTCTTCCAGCCTTCCTTCC-3′ and reverse 5′-CGGACTCGTCATACTCCTGCT-3′. 
The melting temperature was 60°C for all primer pairs. RT-PCR products were 
electrophoretically analyzed on 2% agarose gel and confirmed by direct sequencing. 
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Quantitative Real-Time PCR analysis 
The products of the first strand cDNA synthesis were directly amplified by PCR using 
specific primers for GPRC6A gene to verify cDNA presence and quality. As a negative 
control, cDNA was omitted. GPRC6A expression was quantified by real-time PCR, 
using the Bio-Rad iQ™5 system according to manufacturer instructions with Power 
SYBR® Green PCR Master Mix. Amplification reactions were performed in a 20 μl 
final volume containing 10 μl Power SYBR Green PCR Master Mix, 1 μl primers (10 
μM) and 4 μl (20 ng) cDNA from HEK-293 cells. Amplification was done for 40 cycles. 
After an initial hot start for 10 min each cycle consisted of 15 sec denaturation, 30 
sec annealing at 60°C and 30 sec extension at 60°C.  
To normalize the amount of expressed mRNA the internal housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (primer forward 5’-
AAGGTGAAGGTCGGAGTCAA-3’ and reverse 5’ AATGAAGGGGTCATTGATGG-3’) was 
used and each cDNA product was tested in triplicate. To calculate data we used the 
comparative Ct method for relative quantification (ΔΔCt), which describes the 
change in expression of the target gene in the tested sample relative to a calibrator 
sample from a cDNA library and provides accurate comparison between the initial 
level of template in each sample (Livak et Schmittgen, 2001). Data were analyzed 
with Bio-Rad iQ™5. 
End-point PCR analysis 
An end-point PCR reaction was performed. The PCR mixture consisted of 2,5 μL 
TaqGold Buffer 10X without MgCl2, 1,5 μL MgCl2 (50 mM), 1 μl dNTPs (10 mM), 20 
pmol of each primer, 0,2 μL TaqGold enzyme, sterile H2O in a final volume of 25 μL 
and 4 μl (20 ng) cDNA from HEK-293T cells. The amplification program was as 
follows: denaturing at 94°C for 10 min, 40 cycles each at 94°C for 1 min, annealing at 
56°C for 1 min and extension at 72°C for 1 min, followed by a final extension at 72°C 
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for 10 min. The amplification products were analyzed by staining with SYBR safe 
DNA gel stain, after electrophoresis on 1% agarose gel. 
Flow cytometry analysis 
About 16 hr before the beginning of an experiment, cells were starved in serum-free 
medium. Thereafter, cells were detached mechanically with a scraper (UltraCruz™ 
Cell Scrapers, sc-213229, Santa-Cruz Biotechnology), providing uniform contact with 
all growth surfaces to ensure efficiency and to minimize mechanical strain. All 
sample were rinsed once with PBS + BSA 5%, suspended in serum-free medium, and 
splitted into different tubes. Each sample was incubated for 1 h at room 
temperature according to the different experimental conditions (see “Cell-surface 
receptor binding assays” section). Thereafter, all samples were fixed in 4% 
paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA) in PBS for 15 min  and rinsed 
in PBS + BSA 5%. All samples were then incubated for staining-procedure with a goat 
anti-OC polyclonal antibody (1:100; sc-18319, Santa-Cruz Biotechnology) or a goat 
anti-SHBG polyclonal antibody (1:100; sc-32467, Santa-Cruz Biotechnology) for 15 
min at room temperature. Primary immunoreaction was properly detected by the 
use an  anti-goat biotinylated secondary antibody (1:200; Dako Italia) for 15 min at 
room temperature and, successively, after rinsed in PBS + BSA 5%,  with a 
streptavidina/FITC-conjugated tertiary reagent (1:200; DBA Italia) for other 15 min 
at room temperature. Multiple biotinylated secondary antibodies molecules can be 
conjugated to a protein of interest, which allows binding of multiple streptavidin-
coniugated reagents, increasing the sensitivity of detection of the protein of 
interest. Samples were finally analyzed with the FACScan flowcytometer (BD 
Biosciences, San Jose, CA, USA) and 10,000-15,000 events gated in the region of the 
specific cell type were acquired (Figure 10). The value of fluorescence intensity 
subtending the highest 1% of the untreated control curve was considered as the 
threshold for quantification of specific agonist binding (Oury et al., 2011).  
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Figure 10. Flow cytometry analysis on HEK-293T cells. Morphological gate (left panel) and 
establishment of value of fluorescence intensity subtending the highest 1% of the untreated control 
curve (right panel), as threshold for quantification analysis of specific agonist binding. 
Immunofluorescence assays 
Cells were cultured in a 8-well flat-bottomed microculture dish as previously 
described in the “Cell line HEK-293T” section. About 16 hr before the beginning of an 
experiment, cells were rinsed once with PBS + BSA 5% and starved in the same 
condition described  in the “Flow cytometry analysis” section. Thereafter, all sample 
were rinsed with PBS + BSA 5% and incubated for two hours at room temperature 
according to the different experimental conditions. The samples were fixed in 4% 
paraformaldehyde (Sigma-Aldrich) in PBS for 15 min at room temperature and rinses 
in PBS + BSA 5%. All samples were then treated for staining-procedure by co-
incubation with the respective primary antibody (1:100) (see “Cell-surface receptor 
binding assays” section). Primary immunoreaction were detected as previously 
described. 
Finally, samples were counterstained with 40,6-diamidino-2- phenylindole (DAPI, 
1:10,000; Boehringer), mounted on microscope slides with antifade buffer, and 
analyzed by laser confocal microscopy VICO fluorescence microscope (Nikon, 
Firenze, Italy). 
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Cell-surface receptor binding assays 
A single concentration of ligand (usually an agonist) was used in every assay tube. 
The ligand (e.g. undercarboylated osteocalcin) was used at a low concentration, 
usually at or below its dissociation constant (Kd) value. The level of specific binding 
of the ligand (e.g. undercarboylated osteocalcin) was then determined in the 
presence of other competing compounds (e.g. SHBG), in order to determine the 
specificity with which they competed for the binding of the previous ligand. In order 
to verify the working hypothesis, the samples underwent to the following 
experimental conditions (Table 3): 
Sample 
(1h at room temperature) 
Medium without serum 
SHBG 73,7ng/mL 
ucOC 10ng/mL 
ucOC 10ng/mL + SHBG 50-fold [cOC] 
cOC 10ng/mL 
cOC 10ng/mL + SHBG 50-fold [cOC] 
Table 3. Cell-surface receptor binding assays. Different experimental conditions. The concentration of 
SHBG is equimolar to  osteocalcin. cOC, carboylated osteocalcin; ucOC, undercarboylated osteocalcin; 
SHBG, sex-hormone binding globulin. 
A group of samples were pre-treated for 30 min at room temperature with a rabbit 
anti-hGPRC6A polyclonal antibody (H-68, sc-67302; Santa-Cruz Biotechnology) in an 
oversaturating concentration in order to better assess the specificity of the binding. 
hGPRC6A antibody raised against an epitope corresponding to amino acids 343-410 
mapping within an extracellular domain of GPRC6A receptor of human origin. 
hGPRC6A antibody was recommended for detection of GPRC6A receptor of human 
origin by western blot, immunofluorescence, and ELISA assays. 
A preparatory phase, in order to titolate the optimal concentration of the different 
reagents balancing specificity and sensitivity, was performed. 
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STATISTICAL ANALYSIS 
All statistics were performed using SPSS software (version 19.0; SPSS Inc. Chicago, IL, 
USA) and R software (version 2.11.0; Free Software Foundation, Auckland, CA, USA). 
Comparisons between biochemical markers and clinical variables were made using 
Mann-Whitney U and Kruskall-Wallis non parametric tests across groups. 
Relationships between continuous markers and variables were assessed using 
nonparametric Spearman’s ρ correlation test. A multiple regression model using the 
ucOC/OC ratio as the dependent variable adjusted for presence of diabetes was 
performed. Variables are given as mean ± standard error of the mean (SEM), except 
when otherwise indicated.  
A multivariate clustering analysis on 3-D protein structure alignment analysis 
outputs was performed. Cluster analysis is a major technique for classifying a 
‘mountain’ of information into manageable meaningful piles. It is a data reduction 
tool that creates subgroups that are more manageable than individual datum. Like 
factor analysis, it examines the full complement of inter-relationships between 
variables. Each alignment (of the 3-D protein structure alignment analysis) was a 
point in the ideal 188 dimensions space (one for each amino acid) of SHBG amino 
acid residues to which the different osteocalcin models were compared. One case 
was the output of an algorithm, having categorized each amino acid as a nominal 
variable in accordance to the similarity to osteocalcin (0 not comparable; 1 
comparable). 
Comparison of experimental data was done by the unpaired 2-tailed Student t test 
after acceptance of normal distribution with the Kolmogorov-Smirnov test. Data are 
shown as the mean ± standard deviation of the mean (SD). All experiments were 
performed in triplicate, except when otherwise indicated. The significance level was 
set as P value < .05.  
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RESULTS 
Clinical and biochemical characteristics of the patients 
Seventeen patients were overweight (19%, BMI = 25.0-29.9 kg/m2), 21 class I-II 
obese (23%, BMI = 30.0-39.9 kg/m2), and 25 class III obese (27%, BMI ≥ 40.0 kg/m2) 
according to the WHO-recommended classification for BMI (WHO, 2000).  
Differences between clinical and biochemical characteristics among all groups, 
overweight and obese patients (BMI ≥ 25.0 kg/m2) vs. healthy controls are showed 
in the table (Table 4). Body weight (data not shown), BMI, systolic and diastolic 
blood pressure (data not shown), leptin, total and free T, SHBG, E, ucOC, and 
ucOC/OC ratio were different between all groups, whereas there were no 
differences in body height (data not shown), total OC, and cOC across groups. Within 
each group, patients with diagnosis of diabetes were as follows: 1/17 (5.9%) in 
overweight patients, 1/21 (4.8%) in class I-II obese patients and 4/25 (16%) in class 
III obese patients.  
Free T was negatively correlated to BMI (ρ = -.71, P < .05) and positively correlated 
to ucOC/OC ratio (ρ = .22, P < .05) in the whole cohort, but no correlation was found 
with cOC (ρ = .11) and ucOC (ρ = .19). The positive correlation between free T and 
ucOC/OC ratio was not significantly influenced by the presence of diabetes through 
a multiple regression model (P = 0.12 using Fisher’s test comparing the simple 
model, without inclusion of diabetes as independent variable, β = .20 and SE = .12, 
to the multiple model, including diabetes, β = .23 and SE = .12). There was no 
correlation between either total T or SHBG and cOC (ρ = -.066 and -.51, 
respectively), ucOC (ρ = .18 and .04, respectively) or ucOC/OC ratio (ρ = .19 and .02, 
respectively). There was no significant correlation between E and ucOC or E and 
ucOC/OC ratio (ρ = -18 and -15, respectively). Leptin was negatively correlated to 
total T (β = -.68, P < .001), free T (β = -.60, P < .001) and SHBG (β = -.51, P < .001), 
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and positively with E (β = .47, P < .001), but we could not find any correlation 
between leptin and osteocalcin in different γ-carboxylated forms. 
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Osteocalcin and SHBG sequence alignment analysis 
Sequence alignment between template sequences SHBG (170 aa, first line) and OC 
(49 aa, third line) showed an alignment length of 48 amino acid residues, with an 
identical length of 11 and a sequence identity of 22.9% (Figure 11).  
 
Figure 11. Sequence alignments of SHBG (first line) and osteocalcin (third line) with NW-align. Amino 
acid residues are classified with the one-letter code. 
Crystallographic structure of osteocalcin and SHBG   
The electronic database of Medline was searched via Structure with the search 
terms (osteocalcin [All Fields]) and (OCN [All Fields]) and (OC [All Fields]), or (sex 
hormone binding protein [All Fields]) and (SHBG [All Fields]). Additional hand 
searching of articles, reference texts and reference lists was also performed. From a 
total of 54 and 42 retrieved citations, respectively 0 and 6 results were classified as 
relevant and were subjected to full review.  
Despite no article depicted the crystallographic structure of SHBG alone (Table 5), 
SHBG in complex with dihydrotestosterone (DHT) was chosen, representing the 
endogenous ligand that binds with the greater affinity to SHBG (KD 5.5 109 M-1), to 
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undergo to analysis of 3-D protein alignments analysis with human osteocalcin. The 
crystallographic structure of SHBG in complex with DHT was retrieved from the 
Protein Data Bank (PDB code entry 1D2S). 
PDB code Description Reference 
1D2S SHBG in complex  with dihydrotestosterone Grishkovskaya et al. 2000 
1LHU SHBG in complex  with estradiol Grishkovskaya et al. 2002a 
1LHV SHBG in complex  with norgestrel Grishkovskaya et al. 2002a 
1LHW SHBG in complex  with 2-methoxyestradiol Avvakumov et al. 2002 
1LHN SHBG in complex  with 5α-androstane-3β,17α-diol Grishkovskaya et al. 2002 
1LHO SHBG in complex  with 5α-androstane-3β,17β-diol Grishkovskaya et al. 2002 
1F5F SHBG in complex  with zinc Avvakumov et al. 2000 
1KDK SHBG in crystals soaked with EDTA Grishkovskaya et al. 2002b 
1F5F SHBG (tetragonal crystal form) Grishkovskaya et al. 2002b 
Table 5. Crystallographic structure of SHBG in PDB (last update February, the 1st 2012). EDTA, 
ethylenediaminetetraacetic acid; PDB, Protein Data Bank; SHBG, sex hormone binding globulin. 
Human osteocalcin homology modeling 
The homology model of human osteocalcin was built starting from the 
crystallographic structure of porcine osteocalcin (PDB code: 1Q8H) (Hoang et al., 
2003). Due to the high conformational flexibility of the N-terminal in the template 
structure, only the amino acid residues from Pro13 to Val49 could be modelled. The 
resulting human osteocalcin model displayed three α-helices H1(Asp14-Leu25), 
H2(Asp28-Ile36), and H3(Gln39-Tyr46), stabilised by numerous HB involving Asp14, 
Gla17 and Arg20 in α-helix H1, Glu31 and  His35 in α-helix H2, and Glu40 and Arg43 
in α-helix H3. The orientation of α-helices H1 and H2 was locked by a disulphide 
bridge between Cys23 and Cys29 in the protein core. A distinctive structural feature 
of human osteocalcin entailed the asymmetric distribution of positive and negative 
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amino acids within the model structure (Figure 12). A wide negatively charged 
surface (in red) was generated by clustering of acidic amino acids in α-helices H1 
(Gla17, Gla21 and Gla24) and H2 (Asp28, Asp30, and Asp34), whereas a few 
positively charged amino acids (Arg19, Arg43 and Arg44) were located on the 
opposite face of the protein (in blue).  
 
Figure 12. Surface electrostatic distribution on Gla osteocalcin. The charge distribution on the surface 
of molecule is shown. The concentration of acidic residues near the convergence of α-helices H1 and 
H2 produces a localized, highly negative surface region (in red) suited for coupling with cations. This 
suggests that in bone the protein may associate with Ca2+ on the bone mineral surface. C-ter, C-
terminal; H, α-helix; N-ter, N-terminal; blue colour, positively charged surface region; red colour, 
negatively charged surface region. 
The clustering of negative amino acids in Gla osteocalcin is suited for coupling with 
cations, represented by the three Ca2+ ions (Figure 13). 
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Figure 13. 3-D structure of Gla osteocalcin (upper panel, un-complexed with Ca2+; lower panel, 
complexed with Ca2+) and the model validation through MOE version 2010.11 suite. Contact energy 
profile and the Z-Score of the protein backbone dihedrals have been evaluated, being the red line the 
maximum limit accepted. C-ter, C-terminal; N-ter, N-terminal; OC, osteocalcin. 
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Molecular dynamics simulations and Ca2+ binding of osteocalcin 
Classical molecular dynamics (MD) simulations were performed on osteocalcin 
containing three Gla residues at position 17, 21 and 24 (Gla-OC) and in osteocalcin in 
which all Gla residues were replaced by Glu residues (Glu-OC). 
Gla osteocalcin (Gla17/Gla21/Gla24). Gla osteocalcin model, as described in the  
was simulated at 100 ns NVT, 1 atm and 300K. The maximal protein RMSD was 3.5 Å, 
while the minimum fluctuation was 0.9 Å. The average RMSD was 2.1 Å. At the 
beginning of the simulation the C-terminal of the protein pointed into the bulk 
solvent, while after 1 ns the C-terminal interacted with Tyr42. At 10 ns of simulation 
it made a stable polar interaction with Arg19. The latter interaction was broken at 
34 ns and after 50 ns the interaction was reformed, remaining stable until the end of 
the simulation at 100 ns. This final stabilization was due to the participation in the 
polar environment of Gln39 after 67 ns of MD. After the minimization and 
equilibration phase, the three Ca2+ were coordinated by Gla21, Gla24, Asp30, and 
Glu31 forming a “carboxy-cage” bridging α-helices H1 to H2 via Ca2+ bonds. Notably, 
Gla17 did not seem to participate in Ca+2 binding, consistently with the low 
frequency of γ-carboxylation (9%) occurring at this position in human osteocalcin 
(Poser et al., 1980). 
Glu osteocalcin (Glu17/Glu21/Glu24). Applying the same simulation protocol, the 
maximal protein RMSD was 3.3 Å, while the minimum fluctuation was 0.5 Å. The 
average RMSD was 2.3 Å. The disruption in the polar interaction between the C-
terminal carboxylate group and Arg43 after 21 ns and a subsequent (24 ns) HB 
formation between the backbone of Gly47 and the side chain of Tyr42 was 
observed. Despite that this last interaction caused the re-orientation of the C-
terminal towards Arg19 side chain, no stable interaction was formed at this stage as 
observed for Gla osteocalcin. After 34 ns of simulation, Gly47-Tyr42 HB was broken 
and the C-terminal was oriented towards Arg19 after 48 ns; the C-terminal 
carboxylate formed a stable polar interaction with Arg19, which was stabilized by 
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Tyr42. The latter conformation was detectable until the end of MD simulation. Gln39 
was not involved in the stabilization of the C-terminal, as observed with Gla 
osteocalcin. In Glu osteocalcin Ca2+ were coordinated by Glu21, Glu24, Asp30, Glu31, 
and Asp34. The initial interaction between the side chains of Glu31 and His35 was 
broken and replaced by Glu31-Ca2+-Asp34 coordination. Generally, Ca2+ ions moved 
less when compared to the Gla osteocalcin. Moreover, the “carboxy-cage” of Glu 
osteocalcin model oriented the 3 Ca2+ in a different conformation compared to Gla 
osteocalcin, the major difference resulting in the coordination of Ca2+ by Glu24 and 
Asp30 in Glu  osteocalcin. The different calcium-binding network enabled Phe38 in 
Glu osteocalcin to flip around the Cα-Cβ bond, and thus filling a hydrophobic pocket 
formed by Ala33 side chain, the Arg20 methylene-groups and the disulphide bridge 
(Cys23-Cys29), after 25 ns of MD simulation. Re-orientation of Phe38 aromatic side 
chain resulted in a more compact 3-D structure of Glu osteocalcin compared to the 
more open structure of Gla osteocalcin. 
Ca2+ effect in the models of Gla osteocalcin and Glu osteocalcin was monitored 
analysing the protein RMSD over 100 ns of large-scale NVT molecular dynamics 
simulation. Both the protein RMSD of Gla osteocalcin and of Glu osteocalcin in 
presence of Ca2+ (in black) was lower compared to the simulations of the same 
proteins in absence of Ca2+ ions (in red) (Figure 14). 
 
Figure 14. Protein RMSD of Gla osteocalcin (left panel) and Glu osteocalcin (right panel) with 
overtime of 100 ns NVT 300K MD simulations complexed with Ca2+ (black) and un-complexed (red).  
Gla-OC, carboxylated osteocalcin; Glu-OC, uncarboxylated-OC; RMSD, root-mean-square deviation. 
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This effect was particularly underlined within Glu osteocalcin molecular dynamics 
runs and a plausible explanation could be searched in the involvement of the 
counter ions added to the molecular system during the molecular dynamics 
parameterization. Gla osteocalcin had 3 COO- groups more than Glu osteocalcin, 
whose effect was balanced by 3 Na+, which were not present in Glu osteocalcin 
molecular system.  
The average values of the protein backbone RMSD and of the residues 17-21-24 
RMSD of Gla-OC, and Glu-OC models are reported in the table (Table 6). 
 Gla-OC Glu-OC 
Protein backbone RMSD (AVG Å) 2.0 1.9 
Residues 17-21-24 RMSD (AVG Å) 0.8 1.2 
Table 6. Average values of the protein backbone RMSD and of the residues 17-21-24 RMSD of Gla-OC, 
and Glu-OC. AVG, average values; Gla OC, carboxylated osteocalcin; Glu-OC, uncarboxylated OC; 
RMSD, root-mean-square deviation. 
Osteocalcin ClickMD analysis 
A ClickMD RAINBOW RMSD (Cristiani et al., 2011) analysis (Figure 15) over the two 
protein systems analysed indicated for both protein structures high conformational 
changes in the N-terminal and especially in the C-terminal (in green and yellow 
range). Gla osteocalcin showed larger conformational changes compared to not-
carboxylated osteocalcin in absence of Ca2+. This was probably due to the charge 
repulsion due to the presence of the carboxylation. Whereas, Glu osteocalcin 
showed larger conformational changes compared to Gla osteocalcin in presence of 
Ca2+. In particular, Gla osteocalcin exhibited a major stability in the region of the Ca2+ 
interactions. This last observation, together with the above described protein RMSD 
analysis, suggests a potential key role of Glu residues in the protein conformational 
stability: the presence of Ca2+ ions complexed by carboxylated acid glutamic residues 
stabilize the protein conformation of Gla-OC compared to Glu-OC. 
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Figure 15. ClickMD RAINBOW RMSD analysis performed overtime of 100 ns NVT 300K MD. Gla 
osteocalcin (left panels), and Glu osteocalcin (right panels), un-complexed (upper panels) and 
complexed with Ca2+ (lower panels).  Amino acid residues (lateral axis); time (vertical axis); white 
color, RMSD 0 Ȧ; black color, RMSD 14 Ȧ.   
A heatmap analysis (performed with VMD 1.8.7 software) described the analysis of 
trajectories. The heatmap analysis showed unstable (in red/black) and stable (in 
white) amino acid residues across the time, and confirmed the previous observation 
between Gla and Glu osteocalcin: Ca2+ ions seem to influence more the protein 
conformation compared to protein carboxylation (Figure 16). 
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Steered molecular dynamics on osteocalcin carboxy-state and Ca2+ 
binding 
Starting from the average osteocalcin structures obtained during MD trajectories, 
further investigations were carried out through SMD simulations applied on the 
complexes between Ca2+ and all three γ-carboxylated forms of osteocalcin described 
in the literature, respectively Gla osteocalcin, Glu17 osteocalcin (i.e. osteocalcin γ-
carboxylated only on the amino acid residues Glu21 and Glu24),  and Glu osteocalcin 
(Figure 17).  
 
Figure 16. VMD heatmap analysis performed over 100 ns of MD simulation with VMD 1.8.7 software. 
Gla osteocalcin, un-complexed (upper panel) and complexed with Ca2+ (lower-left panel), and Glu 
osteocalcin un-complexed with Ca2+ (lower-right panel). The Ca2+ ions influences more the protein 
conformation compared to the protein γ-carboxylation. COO-, carboxyl group. 
SMD experiments showed the strength of the binding between Ca2+ and osteocalcin 
proteins in a rough and fast evaluation way. Briefly, during an SMD simulation an 
external force was applied to the ligand in the protein complex, in order to facilitate 
its unbinding from the protein. The analysis of interactions of the dissociating ligand 
with its binding region, as well as the recording (as a function of time) of the applied 
forces and the ligand position can yield important structural information about the 
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structure-function relationships of the ligand-receptor complex, binding pathways, 
and mechanisms underlying the selectivity of enzymes. In our simulations a constant 
acceleration (equal to 35,000 pm/ps2) was applied to Ca2+. Different "distance 
profiles" were obtained in relation to the degree of γ-carboxylation of the protein, 
showing a qualitative correlation between the degree of γ-carboxylation of 
osteocalcin and the strength of the Ca2+ binding to the protein. Using the same 
external acceleration on the Ca2+ ions, the unbound process appeared after only 7 ps 
of SMD simulation in Glu osteocalcin, after 14 ps in Glu17 osteocalcin, after 42 ps of 
SMD simulation in Gla osteocalcin. These results suggest that the strength of the 
interactions between Ca2+ and osteocalcin depends on the degree of γ-carboxylation 
of the protein and support the validity of our model. 
 
Figure 17. Glu-OC (A, in blue), Glu17-OC (B, in green) and Gla-OC (C, in yellow) after 20 ps of SMD 
after 20 ps of SMD analysis. The graph (D) represents quantitatively the distance profiles of Ca2+ (red) 
during the SMD. The  amino-acid sequence numbering starts at N-terminal of the homology model 
(i.e. Pro13), thus, e.g., Gla5 correspond to Gla17 of human carboxylated osteocalcin. 
59 
 
Osteocalcin at RP-HPLC and mass analysis 
Human Gla osteocalcin and mice Glu osteocalcin purity and chemical identity, were 
checked by RP-HPLC and mass spectrometry (Figure 18). 
 
Figure 18. Deconvoluted ESI-TOF mass spectrum of LC-MS purified Gla osteocalcin (left panel) and 
Glu osteocalcin (right panel). a.m.u./u.m.a, atomic mass units. 
The results confirmed the available data from the literature (Table 7). 
 
Table 7. Chemical data of human (Human Gla-OCN) and mouse osteocalcin (Mouse Glu-OCN). aa, 
amino acid residue; a.m.u., atomic mass units; MW, molecular weight; ε, absorbance. 
Osteocalcin Ca2+ binding at spectroscopic techniques 
The effect of γ-carboxylation on Ca2+ binding to osteocalcin was investigated by 
using human osteocalcin, containing Gla residues at positions 17, 21 and 24, and 
mouse osteocalcin, where γ-carboxylation does not occur and Gla residues are 
replaced by Glu.  
60 
 
The results of fluorescence spectroscopy in the far-UV region showed that the single 
Trp5 in human Gla osteocalcin in the absence of Ca2+ emitted fluorescence at 350 
nm, indicating that Trp5 was fully exposed to the water solventin (Figure19). Upon 
increasing calcium concentration, the fluorescence of Trp5 was quenched and the 
λmax value was slightly blue-shifted, suggesting that in the presence of Ca2+ the N-
terminal of human Gla osteocalcin undergoes to significant conformational changes. 
Unfortunately, mouse Glu osteocalcin does not contain any residue of Trp; no 
information from fluorescence measurements could be obtained.  
 
Figure 19. Binding of Ca2+ to human Gla osteocalcin monitored by fluorescence spectroscopy in the 
presence of 0.15 M NaCl. Samples were excited at 280 nm and the emission was recorded at 344 nm. 
The fluorescence intensity was recorded as a function of Ca2+ concentration. Each spectrum was the 
average of two accumulations after baseline subtraction.  
The spectra of human Gla osteocalcin and mouse Glu osteocalcin at CD spectroscopy   
exhibited a negative band around 204 nm consistent with a random coil (Figure 20). 
A shift in the negative band to 208 nm, as well as a strong increase in the ellipticity 
(θ) value at 222 nm, was observed when Ca2+ was added. The former results indicate 
that when Ca2+ is added, Ca2+ induces a α-helical conformational shift in both 
proteins with the maximal conformational change occurring at about 3 mM and 28 
mM Ca2+ for human Gla osteocalcin and mouse Glu osteocalcin, respectively. The 
change in ellipticity signal at 222 nm as a function of Ca2+ concentration was 
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obtained (Figure 20). The affinity of human and mouse osteocalcin for Ca2+ was 
determined by CD spectroscopy. The best fit yielded a Kd for Ca2+- human Gla 
osteocalcin of .11 ± .01 mM and a Kd for Ca2+- mouse Glu osteocalcin of 3.64 ± .23 
mM. This data showed that Gla residues bind Ca2+ with an affinity which is over one 
order of magnitude greater than that of Glu residues. 
 
 
Figure 20. Affinity of Ca2+ for human Gla osteocalcin (upper panels) and mouse Glu osteocalcin (lower 
panels) determined by circular dichroism spectroscopy. The ellipticity signal of osteocalcin was 
recorded as a function of Ca2+ concentration. Each spectrum is the average of four accumulations, 
after baseline subtraction. Ellipticity data are expressed as millidegrees without further 
normalization. Θ, ellipticity. 
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Cluster analysis of 3-D alignments between osteocalcin and SHBG 
The output solutions was obtained by the comparison of the 3-D protein structure of 
SHBG (PDB code entry 1D2S) to, respectively, the human internally developed ones 
of Gla osteocalcin and Glu osteocalcin. TM-align, as well as FATCAT algorithm, gave a 
single output; whereas the best five matches scored by TopMatch and 
TriangleMatch were chosen. Overall the output solutions (188 element vectors were 
defined as 0 not comparable, 1 comparable; see “APPENDIX” section) underwent to 
a multivariate cluster analysis (as explained in the “Statistical analysis” section) to 
identify SHBG regions characterized by a good similarity with osteocalcin. The best 
three clusters of the comparisons are summarized in the table (Table 8). 
Proteins Cluster Alignments classified (%) Similarity surface motifs§ 
SHBG/ 
Glu-OC 
1 
2 
3 
35 
25 
40 
33-38; 170-177 
143-155 
15-18; 26-29; 53-56; 159-164 
SHBG/ 
Gla-OC 
1 
2 
3 
15 
60 
25 
171-177 
16-18; 46-56; 142-146; 159-165 
75-85 
§ aa sequences shared by the majority of the alignments classified in the same cluster using SHBG aa sequence 
numbering 
Table 8. Cluster analysis of 3-D alignments between osteocalcin and SHBG. The percentage of the 
solutions classified in each the best three clusters are shown. 
Overall, three regions of similarity were identified between SHBG and human Gla or 
Glu osteocalcin. However, amino acids residues from 75 to 85 of SHBG correspond 
to the region implied into the dimerization of SHBG. Representative positions of 
testosterone are presented to support the previous interpretation (Figure 21 e 22). 
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Figure 21. Analysis of 3-D alignments SHBG/undercarboxylated osteocalcin (OC). Examples of 
alignments which were randomly chosen. 
 
 
 
Region Example alignment 
1 OC     16       35 
       LEPRRE … HIGFQEAYR 
SHBG   DLTKIT … DSWLDKQAE 
       33       168  
 
2 OC     25      41 
       LNPDC … AYRRFYGPV 
SHBG   GGLLF---PASNLRLPL 
       144         
 
3 OC     16       
       P-L---EPRREVCELNPDCDELADX 
SHBG   PPA … E--V-RT-WDPE--GVIFY 
       13    45     
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Figure 22. Cluster analysis of SHBG/undercarboxylated osteocalcin (left panel) and 
SHBG/carboxylated osteocalcin alignments (right panel) on SHBG 3-D structure.  Representative 
positions of testosterone are presented to support the interpretation 
Osteocalcin and SHBG (dimer)-GPRC6A receptor docking analysis 
The best-scored comparative protein structure model describing the extracellular 
loops and upper third of the trans-membrane bundle of GPRC6A receptor was used 
as the docking site, due to the lacking of the crystallographic resolution of GPRC6A 
receptor. Either SHBG or Glu osteocalcin was docked to GPRC6A receptor to 
determine the preferred binding site on the receptor. The best five outputs of each 
of the three docking algorithms underwent to a frequency analysis of the amino 
acids involved in the predicted surfaces interaction SHBG-GPRC6A receptor (Figure 
23). The three highly predicted interfaces were, respectively, 145-161, 59-67 and 19-
41, numbered according the SHBG sequence amino acid residues (Figure 24). 
Inferring about those showing a 3-D protein structure osteocalcin-like, only the first 
and the latter showed it. In particular, the first one included amino acids Gly145 
Leu145 Leu147 Phe148 Pro149 Ala150 Ser151 Asn152 Leu153 Arg154 Leu155 
Pro156 Leu157 Val158 Pro159 Ala160 Leu161, forming a loop between the β-motifs, 
opposite to the steroid-binding site (Figure 25). The central part of the sequence was 
predicted with a rate above 50% compared to the other amino acid residues of 
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SHBG. The nature of the amino acids (e.g. Pro) of the predicted interface could 
support the synthesis of a potentially structured peptide.  
 
 
Figure 23. Best five outputs of SHBG (dimer)-GPRC6A receptor docking analysis with GRAMM-X; 
PatchDcock and ZDOCK algorithms. The predicted interfaces are numbered according to the 
sequence of SHBG amino acid residues.  
 
 
Figure 24. Frequency of the prediction of each amino acid residues of SHBG as shown by the best 
outputs of the SHBG (dimer)-GPRC6A receptor docking analysis. Green color represents the amino 
acid residue of SHBG which participated to osteocalcin-like (OC-like) motifs. aa, amino acid residue. 
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Figure 25.  Cartoon of SHBG monomer. The amino acid residues from Gly145 to Leu161 are shown as 
sticks. The former amino acid residues (the most predicted interface in SHBG (dimer)-GPRC6A 
receptor docking analysis) form a loop between the β-motifs, opposite to the steroid-binding site. 
Gprc6a gene expression in HEK-293T cells 
End-point PCR analysis of amplified cDNA extracted from HEK-293T showed that 
Gprc6a is endogenously expressed (Figure 26). A clear band could be observed with 
each of the three primers; the quality of the experiments was confirmed by the 
expression of the internal housekeeping gene, glyceraldehyde-3-phosphate 
dehydrogenase (GADPH).  
 
Figure 26. End-point PCR of Gprc6a gene expression from HEK-293T cells with three pairs of primers, 
respectively Gprc6a_1, Gprc6a_3, and Gprc6a_1ART. ctrl, negative control; GADPH, glyceraldehyde-3-
phosphate dehydrogenase. 
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To confirm these results, RT-PCR experiments were performed. A human kidney 
library served as a positive control. The expression of Gprc6a was further confirmed, 
despite to a lower level compared to the human kidney library (data not shown). 
GPRC6A receptor protein expression on HEK-293T cells 
GPRC6Areceptor expression on the surface of HEK-293T cells was confirmed by 
immunofluorescence assay and VICO technology to minimize the influence of the 
background signal (Figure 27). The staining of GPRC6A appeared as a specific dotted 
signal. 
 
Figure 27. Immunofluorescence (confocal fluorescence microscope) for GPRC6A receptor on HEK-
293T cells. Negative control (left panel) and example of a sample treated with Ab anti-GPRC6A 
(green). Counterstaining of nuclei was performed with 4,6-diamidino-2-phenylindole (DAPI) (blue). 
Scale bars: 20 μm. 
Characterization of osteocalcin and SHBG binding on HEK-293T cells 
A binding assay was performed on HEK-293T cells to evaluate the binding of 
undercarboxylated osteocalcin, carboxylated osteocalcin and SHBG, respectively, 
and any non-specific binding. Undercarboxylated osteocalcin, carboxylated 
osteocalcin and SHBG binding were confirmed by immunofluorescence assay and 
VICO technology, with SHBG and undercarboxylated osteocalcin showing a higher 
signal (Figure 28 and 29).  No meaningful signal was detected when the samples 
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were pre-incubated with an antibody anti-GPRC6A, and thereafter treated with 
osteocalcin. 
 
 
Figure 28. Immunofluorescence (confocal fluorescence microscope) for osteocalcin binding on HEK-
293T cells. Negative control (left panel); example of a sample treated with osteocalcin (green) 
(central panels; ucOC upper panel, cOC lower panel); example of a sample pre-incubated with Ab 
anti-GPRC6A (right panels). Counterstaining of nuclei was performed with 4,6-diamidino-2-
phenylindole (DAPI) (blue). Scale bars: 20 μm. 
Interestingly, the signal was meaningfully decreased also when the former pre-
incubated samples (i.e. antibody anti-GPRC6A) were treated with SHBG (Figure 29). 
 
Figure 29. Immunofluorescence (confocal fluorescence microscope) for SHBG binding on HEK-293T 
cells. Negative control (left panel);  example of a sample treated with SHBG (green) (central panel); 
example of a sample pre-incubated with Ab anti-GPRC6A (right panel). Counterstaining of nuclei was 
performed with 4,6-diamidino-2-phenylindole (DAPI) (blue). Scale bars: 20 μm. 
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Osteocalcin vs. SHBG binding assay on HEK-293T cells 
A binding assay was performed on HEK-293T cells to evaluate any competition for 
the same binding site between, respectively, undercarboxylated osteocalcin, 
carboxylated osteocalcin and SHBG. The co-incubation both of ucOC and cOC with 
an excess of SHBG (50-fold equimolar) showed a meaningful qualitative decrement 
of the signal detected by the primary antibody anti-osteocalcin by 
immunofluorescence assay and VICO technology (Figure 30).  
In a parallel experiment performed by flowcytometry assay was quantified a relative 
decrement by the mean staining signal of respectively 85% (for ucOC) and 37% (for 
cOC) when samples were co-incubated with an excess of SHBG (100-fold equimolar). 
 
 
Figure 30. Immunofluorescence (confocal fluorescence microscope) for osteocalcin vs. SHBG binding 
on HEK-293T cells. Negative control (left panel);  example of a sample treated with osteocalcin 
(green) (central panels; ucOC upper panel, cOC lower panel); example of a sample co-incubated with 
osteocalcin and an excess (50-fold) of SHBG (right panels). Counterstaining of nuclei was performed 
with 4,6-diamidino-2-phenylindole (DAPI) (blue). Scale bars: 20 μm. 
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DISCUSSION 
Our study shows for the first time the existence of the competition for a specific 
binding site between osteocalcin and SHBG on human cells expressing GPRC6A 
receptor, which was supported by a computational prediction analysis. 
Concurrently, our clinical data show an imbalance between the γ‑carboxylated 
forms of osteocalcin in a cohort of hypogonadic obese and overweight patients, with 
decreased levels of SHBG and altered levels of the other sex hormones.   
Homology between protein molecules can be detected by similarities in function, 
sequence, or structure (Schneider and Stephens, 1990; Murzin, 1998; Thornton et 
al., 1999). In the current study we started to develop our working hypothesis from 
genetic studies in mice (Lee et al., 2007; Oury et al., 2011). The supernatant of 
cultured wild-type osteoblasts was able to increase testosterone production by 
Leydig cells to far greater levels than those observed for other mesenchymal cells 
(Oury et al., 2011). Moreover, the supernatant of Osteocalcin-/- osteoblast cultures 
was ineffective in promoting testosterone production in Leydig cells (Oury et al., 
2011). The higher osteocalcin expression was due to the stimulation of all genes 
necessary for testosterone biosynthesis in Leydig cells (Oury et al., 2011). 
Accordingly, circulating testosterone levels were low in Osteocalcin-/- mice and were 
high in Esp-/- mice, indirectly confirming the importance of the different γ-
carboxylated forms of osteocalcin. Whereas an abundance of studies have tried to 
assess the possible relationship osteocalcin and energy metabolism in humans, data 
are lacking concerning osteocalcin and endogenous sex hormones. In our study we 
described for the first time a positive correlation between the ratio  
undercarboxylated osteocalcin/total osteocalcin and free testosterone, but we did 
not find a direct correlation between undercarboxylated osteocalcin and free 
testosterone. The latter could be due to changes that are related to metabolism or 
vitamin K intake, despite that our inclusion criteria excluded patients taking drugs 
72 
 
known to influence bone and calcium metabolism, or with hepatic failure and 
dietary derangements. The use of the ratio ucOC/OC could likely represent a more 
sensible parameter to describe the overall variation in osteocalcin pattern in 
pathophysiological condition with a multiple aetiology. The effects observed in mice 
with implanted osmotic minipumps containing undercarboxylated osteocalcin were 
seen, in fact, with an increase of undercarboxylated osteocalcin only to 14% (Ferron 
et al., 2010), which is within the intraindividual variation that is normal in humans 
consuming a varied diet. In our cohort there was a parallel decrement of free 
testosterone and SHBG, but we did not find a correlation between SHBG and 
undercarboxylated osteocalcin or ucOC/OC. The latter observation is not against our 
hypothesis. Free testosterone in our study is a direct expression of SHBG levels, 
because it was estimated by calculation from total testosterone and SHBG 
concentrations (Vermeulen et al, 1999). Moreover, the regulation of SHBG 
expression is still not clear and is multifactorial. In vitro studies have demonstrated, 
for example, that SHBG secretion is not only under the control of E and T stimulation 
(the previous exerting it in a dose-dependent manner whereas the second in a 
biphasic one) (Edmunds et al., 1990; Wallace et al. 2012), but is also under the 
control of, e.g., insulin and other hormone inhibition (Plymate et al. 1988; Wallace 
et al. 2012).  
SHBG is specific for humans, whereas the plasma carrier protein for sex steroids in 
mice has not been characterized. Multiple evidence suggests that SHBG has 
functions in addition to that of regulating circulating concentrations of free sex 
steroids and their transport to target tissues. SHBG binds to plasma membranes, 
suggesting the presence of a specific plasma membrane receptor (Strel'chyonok et 
al. 1984). The binding of SHBG to plasma membranes has been demonstrated in a 
limited number of tissues, including prostate, proximal convoluted tubule cells of 
the kidney, liver and epididymis, largely correlating with tissues which are 
responsive to the sex steroids bound to SHBG (Fortunati et al., 1992). Unbound 
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SHBG binds to the SHBG receptor and it has been shown that the stronger the 
affinity of the sex steroid ligand for SHBG, the greater the inhibition of its interaction 
with the SHBG receptor (Rosner et al. 1988). The mechanism of action has not been 
elucidated yet, and it is possible that after SHBG binds to the SHBG receptor either a 
sex steroid then binds to SHBG and the complex is internalized, allowing delivery of 
the sex steroid to the nucleus, or SHBG directly exerts an effect on the cell, acting 
itself as a hormone (Rosner et al. 2010). The SHBG receptor is thought to be a G 
protein-coupled receptor, based on indirect evidence that shows that (i) when an 
appropriate steroid bound to the complex SHBG-SHBG receptor there was a rapid 
rise in cAMP (Nakhla et al. 1990; Nakhla et al., 1994; Nakhla et al. 1995); (ii) the 
exposure of cell membranes containing SHBG receptor to a non-hydrolysable analog 
of guanosine triphosphate (guanylyl-59-imidodiphosphate) caused a substantive 
decrease in the binding to the complex SHBG-SHBG receptor (Nakhla et al., 1999); 
and (iii) there was a reduction in cAMP concentration when the Gα subunit was 
replaced by a mutant form (i.e. as[Gly225Thr] and as[Gly226Ala]) which 
ineffectuated the signal transduction (Nakhla et al., 1999). In the current study we 
demonstrated that HEK-293T cells express GPRC6A receptor both at a genetic and 
protein level. Moreover, the pre-incubation of HEK-293T samples with an antibody 
anti-GPRC6A led to a meaningfully decrement of the fluorescence signal associated 
to the binding of SHBG. Despite that this is not conclusive, the current results tempt 
us to speculate that GPRC6A receptor could represent the putative SHBG receptor 
or, at least, SHBG can bind also to this protein. Conclusive results, however, will be 
obtained only by (i) demonstrating GPRC6A protein expression with western blot 
analysis; (ii) knocking down gene expression with, e.g., specific siRNA transfection, 
and the subsequent analysis of the fluorescence signal associated to the binding of 
SHBG to HEK-293T cells, or to another cell type expressing GPRC6A (e.g. LNCaP 
cells); and (iii) performing functional studies showing, e.g., a rapid rise in cAMP 
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when an appropriate steroid binds to the complex SHBG-SHBG receptor in an 
appropriate cell model (e.g. HEK-293T or LNCaP cells).  
The demonstration that HEK-293T cells express GPRC6A is of particular importance, 
because HEK-293T cells represent an appropriate model to study the interaction 
between undercarboxylated osteocalcin and GPRC6A receptor, the former binding 
to their surface with the same pattern of expression as the latter (i.e. dotted signal 
at immunofluorescence assay). Interestingly, no other research group has ever 
reported a western blot analysis showing the protein expression of GPRC6A in the 
different cellular and ex vivo samples, e.g. mouse and human Leydig cells (Oury et 
al., 2011); RWPE-1 and LNCaP cells (Pi et Quarles, 2012b); transfected HEK-293 
overexpressing Gprc6A (Pi et al., 2011); and mouse TC-6 pancreatic β-cells (Pi et al., 
2011). Although Pi et al. state that HEK-293 do not express Gprc6a (Pi et al., 2010; Pi 
et al. 2011; Pi et Quarles, 2012a), our results do not show this. We obtained good 
expression using the same pair of primers and positive results using other two 
different primers at end-point PCR, as well as the primer Gprc6a_1 at quantitative 
RT-PCR analysis. Our immunofluorescence assays showed a pattern similar to those 
in testis coronal sections reported by Oury et al. (Oury et al., 2011), and the 
disappearance of the signal after pre-treatment with an antibody anti-GPRC6A 
support both the GPRC6A receptor expression and the undercarboxylated 
osteocalcin specificity binding. As previously explained, HEK-293T cells were 
generated by a human kidney cell line by transfection of adenovirus DNA; 
Wellendroph et al. reported that Gprc6a is expressed in mature cells of the kidney 
(Wellendorph et Bräuner-Osborne, 2004), and cytogenetic instability has been 
reported in the literature for some cell lines of HEK-293. 
Structural motifs, including domain arrangements or small molecule binding pockets 
determine the biological function of protein families. The quality of a predicted 
structure partially depends on sequence similarity to the template structure and, 
despite the observed sequence identity above 20% between SHBG and osteocalcin, 
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a close to optimal sequence alignment can only be obtained for closely related 
protein sequences with identities over 40% (Sanchez et Šali, 1997), and a poor 
precision is seen for homologues with a sequence identity below 30%. As sequence 
similarity decreases, in fact, the alignment becomes more uncertain and is likely to 
contain an increasingly large number of gaps and alignment errors (Rost, 1999; 
Marti-Renom et al., 2000; Elofsson, 2002). In the current study we investigated 
possible protein-protein interaction predictors with a more appropriate and efficient 
3-D protein structure alignment analysis between the crystal structure of SHBG and 
the osteocalcin model of the 3-D protein structure that was internally developed 
and validated. The two proteins, in fact, are largely different not only for the 
sequences with identities, but also from the dimension (40.5 KDa vs. around 5.8 
kDa), and the secondary structure, which is constituted mainly of β motifs in SHBG 
vs. three α-helices in osteocalcin (Grishkovskaya et al. 2000; Hoang et al. 2003). 
Moreover, SHBG exerts its actions as a homodimer, whereas circulating osteocalcin 
seems to exist as a monomer in vivo (Strel'chyonok et Avvakumov, 1990; Hoang et 
al., 2003). Loops and side chains of SHBG have been hypothesized be necessary for 
the interaction with plasma membrane receptors in target tissues, despite that they 
are not essential for the steroid-binding activity of SHBG (Strel'chyonok et 
Avvakumov, 1990). Interestingly, inferring the results both from the cluster analysis 
of protein-protein alignments and those of the docking analysis, the predicted 
structure osteocalcin-like of SHBG is formed by a sequence of amino acids rich in 
proline residues forming a loop between the β-motifs, opposite to the steroid-
binding site. Despite the small homology site and the lack of information about the 
site of interactions between osteocalcin and GPRC6A receptor, the osteocalcin 
displacement by excess SHBG in the experiments in vivo support our hypothesis. 
Moreover, in the preliminary experiment at the flow cytometry analysis, the relative 
displacement of osteocalcin by the excess of SHBG was higher for the 
uncarboxylated form than for the carboxylated one, which could resemble the 
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higher specificity for the binding, despite the minor structural difference in our 
molecular modeling studies developed using the amino acid residues from Pro13 to 
Val49.  
Our experiments describe the structure of human osteocalcin, in its carboxylated 
and undercarboxylated forms for the first time. Recent studies on porcine 
osteocalcin revealed an excellent surface complementarity between the Ca2+ 
coordinating surface of osteocalcin and the prism face of hydroxyapatite, suggesting 
that Gla osteocalcin may also show selective binding characteristics to 
hydroxyapatite (Hoang et al. 2003). Our results extend this behaviour about Ca2+ 
affinity to human osteocalcin, and partially explain the lower affinity for 
hydroxyapatite exerted by undercarboxylated osteocalcin. The human Glu 
osteocalcin obtained through homology modelling based on 1Q8H porcine template 
(Hoang et al. 2003) has similar features previously described for the Gla osteocalcin 
model. Protein structures had high conformational changes in N-terminal and 
especially in the C-terminal, depending both on Gla residues and Ca2+ interactions. 
Ca2+ ions have a role in stabilizing the protein conformation of osteocalcin, which is 
supported by the experimental data of the current study describing the Ca2+-
dependent conformational changes in both human Gla osteocalcin, and mouse Glu 
osteocalcin. In particular, the spectroscopic measurements demonstrated that Ca2+ 
binding to osteocalcin results in a dramatic increase of α-helical secondary structure 
and that the N-terminal undergoes significant conformational changes with 
increasing concentration of Ca2+. Interestingly, previous studies in fish osteocalcin 
similarly described that α-helical content of teleost osteocalcin increases and β-
sheet structure decreases upon Ca2+ binding (Nishimoto et al. 2003). The 
experimental analyses have also shown that the presence of γ-carboxylated glutamic 
acid residues significantly modifies the Ca2+ binding capacity of human osteocalcin in 
agreement with the molecular dynamics data, as exemplified by, e.g., ClickMD 
RAINBOW RMSD analysis. Specifically, in the absence of Ca2+ Gla osteocalcin seem to 
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have a greater instability than Glu osteocalcin, probably attributable to the charge 
repulsion due to the presence of the carboxylation (i.e. COO- groups). On the 
contrary, however, when the Ca2+ binds to the molecule, Gla osteocalcin acquire a 
higher rigidity compared to Glu osteocalcin. Overall, the influence of the binding of 
Ca2+ on the structure of the osteocalcin is stronger than the presence of γ-
carboxylated glutamic acid residues, as exemplified by the heatmap analysis. One 
limitations of our and other studies (Hoang et al. 2003), however, is the lack of 
information about the N-terminal in the template structure. N-terminal, in fact, 
could not be modelled due to the high conformational flexibility. Moreover, due to 
the lack of commercially available human uncarboxylated osteocalcin, we were 
forced to perform wet chemistry analysis with mouse uncarboxylated osteocalcin. 
Despite the high homology (i.e. 88%) the lack, for example, of Trp-residue at 
position 5 prevented to resolve possible conformational changes due to Ca2+ binding 
at fluorescence spectroscopy in the far-UV region for osteocalcin, and a species-
specificity should caution us in interpreting the results of the in vitro experiments. 
Conformational changes due the Ca2+ binding could have important effects at the 
level of the interactions between Glu osteocalcin and GPRC6A receptor. As 
previously explained, in fact, GPRC6A receptor senses Ca2+ via orthosteric binding 
sites in the VFTM. Moreover, Pi et al. showed how osteocalcin (up to 40 ng/ml) had 
no effect at sub-threshold extracellular Ca2+  (≤ 1.0 mM), and thereafter osteocalcin 
had a dose-dependent effect to stimulate GPRC6A-dependent increments in SRE-
luciferase activity in experiments in vitro (Pi et al., 2005). Allosteric modulators, such 
as osteocalcin, may bind to distinct sites in the transmembrane domain, influencing 
or being influenced by Ca2+ and other extracellular positive cations. Interestingly, the 
serum concentration of human  osteocalcin is approximately 60 mg/L,  assuming the 
average serum concentration of free Ca2+ is about 1.2 mM, and the Kd estimated Gla  
osteocalcin is 90% Ca2+ saturated, and Glu osteocalcin is only 25% Ca2+ saturated. 
We could hypothesize that Glu osteocalcin could reach GPRC6A receptor largely 
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unbound to Ca2+ and then they could interact. Interestingly, also SHBG binds to its 
putative receptor unbound to SHBG, and it undergoes conformational changes after 
the steroid-binding, gaining its biological activity (Rosner et al. 2010). The 
completion of SHBG with osteocalcin could be implicated both in the regulation of 
testosterone synthesis (Oury et al., 2011), or in unravelled pathways. GPRC6A 
activity, in fact, may be modulated by multiple ligands or by mixtures of ligands 
working together, rather than the typical ligand-receptor interaction that 
characterizes most endocrine networks (Pi et Quarles., 2012a). 
Our results did not investigate the functional consequences of the competition of 
SHBG and osteocalcin for the same binding site. Oury et al. hypothesized in a mouse 
model that the binding of osteocalcin to a GPRC6A receptor expressed in the Leydig 
cells of the testes regulates the expression of enzymes that are required for 
testosterone synthesis in a cAMP response element binding (CREB) protein-
dependent manner (Oury et al. 2011). Pi et al. showed that the same receptor, 
GPRC6A, is also functionally important in regulating non-genomic effects of 
androgens in multiple tissues (Pi et al., 2010). Androgens, in fact, act both through 
classical binding to the nuclear receptor regulating steroid response elements in 
gene promoters (modulating gene expression over a period of hours) and by 
exerting illicit rapid (occurring in minutes) non-genomic effects that may also have 
important biological effects in many tissues. (Losel et al., 2003). The molecular 
mechanisms underlying these non-genomic actions are poorly understood, but 
Gprc6a-/- mice exhibit significantly less ERK activation and Egr-1 expression in 
response to pharmacological doses of testosterone in vivo in both bone marrow and 
testis, and different research teams have obtained opposite phenotypic pattern with 
Gprc6a-/- mice (Pi et al., 2008; Wellendorph et al., 2009). However, the surface 
binding testosterone-BSA and GPRC6A receptor was validated both in in vitro 
experiments and at a structural level. GPRC6A receptor, in fact, has a unique pattern 
of hydrophobic residues in the second extracellular loop, which could play a role in 
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specific testosterone binding by the TM bundle of GPRC6A receptor (Pi M. et al. 
2010). SHBG could exert its action by binding independently, as previously 
described, to its putative receptor, which our study has indicate to potentially be 
GPRC6A receptor, and/or by modulating the binding of free testosterone to the 
same receptor that has shown to mediate its non-genomic effects. There are many 
gaps in the knowledge not only of the possible ligand/modulator, but also in the 
downstream of the signaling pathways. GPRC6A receptor is purported to be coupled 
to Gαq and possibly Gαi, and it was shown that testosterone binding resulted in an 
increased ERK activation and intracellular Ca2+ increase (Pi et al., 2010). However, 
GPRC6A receptor is atypical in that, although ERK activation is inhibited by a 
pertussis toxin, GPRC6A receptor fails to inhibit cAMP production in osteoblasts 
(Christiansen et al., 2007; Pi et al., 2005). Moreover, osteocalcin via GPRC6A 
receptor consistently induced cAMP production in Leydig cells to a level comparable 
to that induced by human chorionic gonadotropin, the positive control, but did not 
induce tyrosine phosphorylation, ERK activation, or intracellular calcium (Oury et al. 
2011), suggesting the capacity to also couple to Gαs. Interestingly, as previously 
explained, when an appropriate steroid binds to the complex SHBG-SHBG receptor, 
there is a rapid rise in intracellular cAMP (Nakhla et al. 1990; Nakhla et al., 1994; 
Nakhla et al. 1995). 
Based on the current findings, we are currently knocking down Gprc6a gene with a 
pool target-specific siRNAs, in order to evaluate, after the confirmation throughout 
western blot analysis of the absence of the protein, the specificity of GPRC6A 
receptor binding both for SHBG and osteocalcin. Concurrently, from the structural 
side, we are synthesizing the target peptide that corresponds to the amino acid 
residues from Gly145 to Leu161 of SHBG in order to test its ability to compete with 
the binding of SHBG and osteocalcin in the same cellular model in experiments in 
vitro. The high content of proline residues could guarantee an own structure. The 
final step will be to study the functional consequences of binding of a combination 
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of (i) osteocalcin in different γ‑carboxylated forms and in the presence or absence 
of Ca2+, (ii) SHBG in presence or not of dihydrotestosterone, and (iii) 
dihydrotestosterone alone. According to the literature, an increase in intracellular 
cAMP should be expected, but quantification of other transcriptional effectors 
should not be excluded. 
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CONCLUSIONS 
The approach of whole-organism physiology, namely that all or most organs interact 
together, prompt us to explore new fields on the basis of a spectrum of clinical 
observations, and mouse genetics offer a unique key to open new research field. 
Molecular physiology represents the gold standard to investigate the function, in 
one particular cell type, of one protein or group of proteins, whether they are 
transcription factors, receptors, or hormones. Although to the best of our 
knowledge no molecule identified as a hormone in mice has lost its function in 
humans, gene, protein and enzymes can differ between species and genders as 
taught both by osteocalcin and SHBG.  
The current two-step approach offers a target approach of investigation directly in 
humans, which has the potential to identify novel pathophysiological pathways as 
well as novel therapeutic possibilities, as exemplified by the current data. The 
computational basis of the possible binding of SHBG and osteocalcin has been 
experimentally validated and can directly lead to the synthesis of a peptide, whose 
physiological and therapeutic implications represent a feasible perspective for 
future research in an area of paramount importance, such as the cross-talk between 
bone, energy metabolism, and endogenous sex hormones.  
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APPENDIX 
Output of custer analysis of 3-D alignments Gla-OC and SHBG 
 
 
 
 
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
P P A V H L S N G P G Q E P I A V M T F D L T K I T K T
TopMatch 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
TriangleMatch 0 0 1 1 1 1 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 1 1 1 1 1 1 1 1 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
TWAlign 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
FatCat 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70
S S S F E V R T W D P E G V I F Y G D T N P K D D W F M L G
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 0 0 0 0
1 1 1 1 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 1 1 0 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
0 0 0 0 0 1 0 0 0 0 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100
L R D G R P E I Q L H N H W A Q L T V G A G P R L D D G R W
0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 1 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 1 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
  
   
 
 
101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129
H Q V E V K M E G D S V L L E V D G E E V L R L R Q V S G
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 1 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 1 0 1 1 1 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
H P I M R I A L G G L L F P A S N L R L P L V P A L D G C L
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 1 1
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0
0 0 0 0 0 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 1 1 1
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188
R R D S W L D K Q A E I S A S A P T S L R S C
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
 Output of custer analysis of 3-D alignments Glu-OC and SHBG 
 
 
 
 
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
P P A V H L S N G P G Q E P I A V M T F D L T K I T K T
TopMatch 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
TriangleMatch 0 0 1 1 1 1 1 1 1 1 1 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 1 1 1 1 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
0 0 0 1 1 1 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
TWAlign 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
FatCat 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70
S S S F E V R T W D P E G V I F Y G D T N P K D D W F M L G
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 1 1 1 0
0 0 0 1 1 1 1 1 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 1 0 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 1 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100
L R D G R P E I Q L H N H W A Q L T V G A G P R L D D G R W
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
  
 
 
101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129
H Q V E V K M E G D S V L L E V D G E E V L R L R Q V S G
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
H P I M R I A L G G L L F P A S N L R L P L V P A L D G C L
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 1 0
0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 1 0 1 0 0 0 0
0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 0
0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 0
0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1
0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188
R R D S W L D K Q A E I S A S A P T S L R S C
0 0 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
0 0 0 0 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
